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Abstract: Microglia are highly plastic immune cells which exist in a continuum of activation
states. By shaping the function of oligodendrocyte precursor cells (OPCs), the brain
cells which differentiate to myelin-forming cells, microglia participate in both myelin
injury and remyelination during multiple sclerosis. However, the mode(s) of action of
microglia in supporting or inhibiting myelin repair is still largely unclear. Here, we
analysed the effects of extracellular vesicles (EVs) produced in vitro by either pro-
inflammatory or pro-regenerative microglia on OPCs at demyelinated lesions caused
by lysolecithin injection in the mouse corpus callosum. Immunolabelling for myelin
proteins and electron microscopy showed that EVs released by pro-inflammatory
microglia blocked remyelination, whereas EVs produced by microglia co-cultured with
immunosuppressive mesenchymal stem cells promoted OPC recruitment and myelin
repair. The molecular mechanisms responsible for the harmful and beneficial EV
actions were dissected in primary OPC cultures. By exposing OPCs, cultured either
alone or with astrocytes, to inflammatory EVs, we observed a blockade of OPC
maturation only in the presence of astrocytes, implicating these cells in remyelination
failure. Biochemical fractionation revealed that astrocytes may be converted into
harmful cells by the inflammatory EV cargo, as indicated by immunohistochemical and
qPCR analyses, whereas surface lipid components of EVs promote OPC migration
and/or differentiation, linking EV lipids to myelin repair. Although the mechanisms
through which the lipid species enhance OPC maturation still remain to be fully
defined, we provide the first demonstration that vesicular sphingosine 1 phosphate
stimulates OPC migration, the first fundamental step in myelin repair. From this study,
microglial EVs emerge as multimodal and multitarget signaling mediators able to
influence both OPCs and astrocytes around myelin lesions, which may be exploited to
develop novel approaches for myelin repair not only in multiple sclerosis, but also in
neurological and neuropsychiatric diseases characterized by demyelination.
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Point-by-point 
Reviewer #1: In their manuscript Lombardi et al examine the effects of EV produced by pro- or anti-
inflammatory microglia on oligodendrocytes and remyelination in vitro and in vivo. EV from anti-
inflammatory microglia were beneficial in lysolecithin induced demyelination whereas EV from pro-
inflammatory vesicles had a negative effect on remyelination. In in vitro experiments the authors 
demonstrated that the EV produced by pro-inflammatory microglia could only in the presence of astrocytes 
impair oligodendroglial differentiation. Biochemical fractionation suggested that astrocytes were converted 
into harmful cells by the inflammatory EV cargo, as indicated by immunohistochemical and qPCR analyses 
whereas surface lipid components of EVs promote OPC migration and/or differentiation. The authors 
conclude that microglial EVs are able to influence OPCs and astrocytes and therefore might be exploited to 
develop novel approaches for myelin repair.  
 
Comment 1. The authors performed a large number of interesting and well conducted experiments, but the 
whole set-up is highly artificial and not suitable to address the question whether EV are relevant for the 
course of de-and remyelination in demyelinating animal models or multiple sclerosis. Nevertheless, the 
experiments demonstrate that EV might be a tool to influence the cause of de- and remyelination and in my 
opinion the authors should focus on this aspect of their study  
Reply We understand the reviewer concern. However, our intention was indeed to use this model to 
understand whether EVs could be a tool to influence the remyelination process in which we succeeded as 
pointed out by the reviewer.   
Comment 2. The authors identify EV in EM pictures taken from lysolecithin lesions. Based on this finding they 
polarize microglia in pro- and anti-inflammatory subsets in vitro, collect the secreted vesicles which then 
were infused into lysolecithin lesions using mini-pumps. However, these experiments do not answer the 
question regarding the relevance of the EV identified in the initial EM pictures for de- and remyelination.  
Reply We realize from  the Reviewer’s  comment, that we should have discussed this issue, of which we were 
aware. As now discussed in the revised text (page 14, line 31, results; page 22, line 28, discussion, see also 
reply to comment 7),  although the field of EVs is expanding exponentially, we still lack selective 
pharmacological or genetic tools to inhibit EV production from microglia in vivo and explore the effects of 
endogenous EVs. Consolidated evidence indicates that inhibitors of neutral and acid sphingomyelinases 
decrease EV production in many cell types, including microglia. However, these blockers may interfere per se 
with the remyelination process as they alter the sphingolipid pathway (Verderio C et al, J Lipid Res. 2018). 
Accordingly, we used exogenous EVs produced in vitro from polarized microglia as a tool to explore the action 
of microglial EVs. 
 
Comment 3. How long are EV stable in the mini-pumps?  
 Reply Following the Reviewer’s request, we measured EVs immediately, 1 and 
3 days after resuspension in saline. Nanosight Tracking Analysis showed that 
EV concentration was reduced by about 30% after 3 day resuspension (EV 
concentration = 2.80x108±0.19 at day 0; 2.60x108±0.13 at day 1; 1.90x108± 
0.08 at day 3). These data have been reported in the revised text (page 16, line 
17, results). In addition, we have now clarified in the Methods that the 
minipumps were filled with freshly isolated EVs and implanted into mice within 
a few hours in order to limit EV degradation (page 4, line 27,  methods). 
 
 
Are saline infusions the appropriate control? Why don't the authors use NS-EV 
as they have done for some of the in vitro experiments?  
Reply  
In our opinion, saline is the appropriate control to evaluate whether EVs released by reactive microglia 
influence or not the remyelination process, given that also NS-EVs may have biological activity. NS-EVs are 
the appropriate control to further explore how the activation state of microglia impact EV action. This has 
been made clearer in the revised text (page 18, line 21, results). 
response to reviewer's comments Click here to access/download;response to reviewer's
comments;Response to Referees.docx
We restricted in vivo analysis to EVs produced by microglia with opposite polarization state (i-EVs and MSC-
EVs/IL-4-EVs) while in vitro we extended the analysis to NS-EVs, to further understand how microglia 
activation influences EV action on OPCs. 
 
The authors observe an increase in MBP at day 7; do they also find an increased number of mature 
oligodendrocytes at that time point?  
Reply In response to the Reviewer’s request, we have quantified the densities of Sox10 positive 
oligodendroglial cells which have lost the early progenitor marker NG2 (Sox10+NG2-cells). The analysis 
showed an increase in the density of oligodendrocytes undergoing maturation in MSC-EVs-injected mice 
compared to i-EVs-injected mice, in line with increased MPB staining. Mean cell 
density values of NG2-Sox10+ cells (NG2-Sox10+ cell density: saline, 721.3 ± 88.64; 
i-EVs, 562.0 ± 40.31; IL4-EVs, 755.1 ± 82.13; MSC-EVs, 1080 ± 98.97; One Way 
ANOVA main effect of treatment p=0,0114 with Holm-Sidak's multiple 
comparisons test) are reported in the revised text (page 16, line 29, results) and 
the histogram showing NG2-Sox10+ cell density is provided (see flanking graph) 
for the Reviewer’s perusal. Due to space limitation, we would prefer not to 
include the data in Figure 3. However, if the Editor deems it preferable, we will 
include the histogram in a re-organized Figure 3.  
 
Comment 4. In my opinion, the authors should include the data regarding the young mice injected with EV 
at day 7 into the main part of the manuscript. It is interesting to see that the EV had an effect above 
endogenous remyelination in old, but not young mice. 
Reply We thank the reviewer for this highly relevant comment with which we fully concur, and we have 
included the data obtained in young mice in the main part of the manuscript, as the new Figure 5. 
 
Comment 5. The authors identify S1P as one factor contributing to increased migration in vitro, but not 
differentiation. They conclude from their experiments that other lipid components of the EV membrane are 
responsible for the differentiation promoting effect. I think this is a very interesting finding; but unfortunately 
the authors do not try to further identify the lipids responsible for the differentiation promoting effect. 
Reply. We fully agree with the Reviewer that the identification of the EV lipid(s) responsible for OPC 
differentiation is of great relevance to develop new tools to promote remyelination. However, we think that 
too much work remains to be done to identify the lipid(s), which promote(s) OPC differentiation and myelin 
deposition.  
Using Raman Spectroscopy, we did obtain preliminary data on the lipid composition of EVs. We found that 
phosphatidylcholine, phosphatidylserine, sphingomyelin and cholesterol are predominant molecules in all EV 
spectra with variations in their prevalence in relation to the polarization state of donor cells. However, 
molecular attributions are difficult in complex Raman spectra, and low abundant species cannot be detected 
by this approach. A more specific approach, such as lipidomic analysis, is thus required to validate and extend 
these preliminary data and to define candidate lipids, expressed in i-EVs, IL4-EVs and MSC-EVs and less 
abundant or not present in NS-EVs, which may have pro-differentiating activity. The capacity of identified 
lipid(s) to stimulate OPC differentiation should be then assessed on cultured OPCs and in vivo.  
An alternative approach to identify the lipid(s), which stimulate OPC differentiation, may be to separate main 
lipid classes from the total lipid extract and then further distinguishing between members in the “active” 
families by testing their capacity to promote OPC differentiation. Whatever the approach, the identification 
of the EV lipid(s) responsible for OPC differentiation will take a long time and will be therefore the focus of a 
future study.  
 
Comment 6. The authors describe a shift to A1 astrocytes after addition of i-EV in vitro and claim that the 
same is true for the in vivo situation. However, in vivo they only examined two astrocytic markers; only one 
showed a significant difference; therefore they should be a bit more careful with their conclusion.  
Reply. Following the Reviewer’s suggestion, we more carefully discuss the capacity of i-EVs to induce harmful 
astrocyte transformation in the revised text (line 12 abstract; last two paragraphs page 4, introduction; page 
21, line 13, results; page 24, discussion, line 5). 
  
Comment 7.  The authors should discuss the limitations of their studies. Their experiments are based on the 
generation of EV from polarized microglia. Whether the same EV are generated in vivo remains unclear and 
the experiments are not designed in a way to address this question.  
Reply. We agree with the Reviewer that we lacked in clarity in the discussion of our in vivo experiments. We 
have elaborated our Results (page 15, line 6) and in the discussion (page 23, line 1), sections to address this 
issue.  
 
Reviewer #2: The manuscript deals with a highly interesting and timely topic, the dual role of microglia in 
demyelinating diseases. It is known for a while, that microglia play a dual role, a pro-inflammatory role, 
augmenting tissue damage, and a beneficial role, augmenting remyelination. However, the exact 
mechanisms behind these two effects are largely unknown. In this study the authors found than microglia 
produce extracellular vesicles (EVs or exosomes), which mediate the respective effects depending upon the 
stage of microglia activation. The authors first show the presence of such EVs in demyelinating lesions 
induced by lysolecithin. In the next step it is shown that EVs from inflammatory activated microglia are 
different from those differentiated into an anti-inflammatory phenotype. The first augment demyelination, 
while the second enhance repair. Then the authors show that these EVs do the same in vivo, when they are 
focally injected into the demyelinating lysolecithin lesions. In further in vitro and in part in in vivo studies the 
authors show that EVs from inflammatory activated microglia induce demyelination not directly, but 
indirectly through a pro-inflammatory activation of astrocytes. This effect apparently is induced by cytosolic 
components of the EVs. In contrast, anti-inflammatory activated microglia produce EVs that stimulate OPC 
proliferation and migration and promote remyelination, and they do this directly through the interaction of 
membrane lipid components, which interact with OPCs. Overall the results are highly interesting and 
innovative and are based on a broad multidisciplinary experimental approach, involving both, in vitro and in 
vivo experiments.  
Reply We thank the reviewer for the general appreciation of our study 
 
Although the study is done in a very exhaustive manner, there are two major aspects, which remain 
unsettled. The first is that there is rather little information on how these EVs are really behaving in vivo in 
the context of a demyelinating lesion. It would be nice in such a study to have data on GFP labeled EVs or 
from transgenic animals with GFP labeled microglia to see, how stable the EVs are in an in vivo lesion, how 
they diffuse in the extracellular space of the brain and lesions towards the proper target cells and whether 
the content of the EVs (e.g. GFP) is taken up into the cytoplasm of target cells or whether it stays in the 
extracellular space. Such experiments could be done with GFP labeled EVs in combination with high 
resolution confocal microscopy or immune electron microscopy. 
Reply We thank the Reviewer for these comment and suggestions, which prompted us to analyze the fate of 
GFP-labelled EVs at myelin lesion. Specifically, we analyzed the localization of GFP-labelled EVs by confocal 
microscopy at 2 time points (20 min and 60 min) after injection into the corpus callosum of lesioned mice.  
The resulting data have been described in Results (page 17, line 17), shown in revised Figure S3, and discussed 
on page 22, line 27.  
 
The other shortcoming of the study is that the actual molecules (lipids as well as intracellular components) 
are not definitely identified. Evidence in this respect is so far circumstantial. 
In response to the Reviewer’s comment, we performed additional experiments to ascertain the involvement 
of TNF-a in the pro-inflammatory activation of astrocyte. We used the TNF-a inhibitor Etarnecept (ETN) to 
explore whether the pro-inflammatory effect of i-EVs on astrocytes is strictly dependent on TNF-a cargo both 
in vitro and in vivo. Specifically, we pretreated i-EVs with ETN and maintained the inhibitor during i-EVs 
incubation with cultured astrocyte or i-EVs infusion into the lesions of LPC-treated mice. qPCR analysis for A1 
and A2 astrocytic markers showed that TNF-α inactivation prevented serping 1 upregulation and induced 
PTX3 expression, indicating that i-EVs fail to activate an inflammatory response in the presence of the 
inhibitor. Moreove,r immunofluorescence analysis revealed a significant decrease in the density of C3 positive 
astrocytes in the presence of the inhibitor, although TNF-α inactivation did not prevent the decrease in  the 
density of PTX3 positive astrocytes caused by i-EVs in vivo (Fig. 7e-f). These results are shown in revised Fig 
7c-f, described in Results (page 21, line 13), and highlighted in the discussion page 24, line 5. 
With regard to the comment of the reviewer on the promyelinating action of EVs, please see our response to 
the same concern of Reviewer 1 (comment 5).  
 
In addition there are some points, which should be addressed: 
1) The electron microscopy shown in Fig 1 is not fully convincing. The microglia cell shows some EVs 
immediately beside the cell membrane. Whether there are additional EVs in the parenchyma is not 
clearly visible.  
To the best of our knowledge EVs have never been identified by EM in the brain parenchyma. In the compact 
brain tissue, EV visualization is constrained by the narrow conformation of the extracellular space, consisting 
of a spider web of small gaps filled with interstitial fluid. The chemicals used to preserve the brain tissue 
normally suck out the fluids that fill the spaces between cells, causing further shrinkage of the extracellular 
space (Pallotto M et al., eLife 2015). It is therefore not surprisingly that dark EVs are visible only immediately 
beside the cell membrane in Fig 1a. 
In the isolated microglia (Fig 1c) dark EVs are clearly detectable at distance from the cell membrane thanks 
to massive cell shrinkage and/or the fortuitous expansion of the pericellular space during sample processing. 
To underlie the difficulties in detecting EVs by EM in the brain parenchyma, we have now revised fig1c 
description as follows: “Despite the narrow conformation of the extracellular space commonly constrains EV 
visualization, we observed a dark microglia, infiltrating the lesion, with several blebs at the cell surface and 
surrounded by membrane vesicles in the pericellular space (Fig.1c, arrows), suggesting intense EV production” 
(page 15, line 2). 
 
In the isolated cells it is also not clear, what are really EVs and what are just small cell processes. 
Only 3D EM reconstruction, a technique not available at our Institutes, would prove that the dark EVs 
indicated by arrows in fig 1C, are not connected to the cell by thin processes. However, we would like to point 
out that intense membrane blebbing and formation of membrane protrusion typically occurs in microglial 
cells shedding EVs in response to ATP in vitro (Bianco et al., J Immunol 2005; EMBO J 2009) or in vivo at the 
choroid plexus, as previously described (Verderio et al., 2012; Suppl Fig.8), supporting the extracellular vesicle 
nature of the dark structures indicated by arrows.  
 
2) Figure 4. The electron micrographs shown in Figure to some extent contradict the quantitative data 
shown in j.I n particular the image of i-EVs shows even more myelin than the others, less 
unmyelinated fibers and a fairly normal myelin. It may be that this figure does not come from the 
center of the demyelinated lesion. It is however not clear how the quantitative data from j to m  were 
reached under these circumstances.  
Reply. We thank the Reviewer for noticing this inconsistency. Indeed, the Reviewer is right and the EM 
micrograph selected did not come from the core of the demyelinated lesion. Accordingly, we have now 
replaced the micrograph with  one taken from the center of the lesion (revised Fig 4i, middle panel) as detailed 
in Methods (page 5, line 22). 
We apologize for our lack of clarity in describing the method used to measure g-ratio and myelin thickness. 
We have now specified that g-ratio values are calculated by dividing the axonal diameter to the outer fiber 
diameter including the myelin sheath (page 5, line 24, methods). A scheme showing how we calculated the g-
ratio is now included in the revised Fig 4 (Fig 4k). 
   
3) The FTY data shown in Figure 5 are interesting, they however contradict the postulated remyelination 
promoting effect of FTY from other studies. This should be discussed in more detail. 
Reply. The pan S1P receptor antagonist S-ene-FTY720 Vinylphosphonate used in our study is a molecule 
different from the S1P receptor agonist FTY720, which activates S1P receptors. S-ene-FTY720- 
Vinylphosphonate is a pure antagonist of all S1P receptors. It binds to S1P receptors and prevent their 
activation by endogenous S1P.  We have modified the relevant part of the discussion to further emphasize 
this. 
 
4)      I am not fully convinced by the data shown in Figure 7. As figure B shows the number of 
fluorescence dots is very low. It is not clear, how under these circumstances EVs % can be calculated in c. In 
addition, not significant results are documented in figure c. Thus, this part could be deleted in its present 
form. 
Reply. Following the Reviewer’s suggestion we have deleted panel B and C in the revised Figure 7 and modified 
the text accordingly. 
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ABSTRACT 
 
Microglia are highly plastic immune cells which exist in a continuum of activation states. By shaping the function of 
oligodendrocyte precursor cells (OPCs), the brain cells which differentiate to myelin-forming cells, microglia participate 
in both myelin injury and remyelination during multiple sclerosis. However, the mode(s) of action of microglia in 
supporting or inhibiting myelin repair is still largely unclear. Here, we analysed the effects of extracellular vesicles (EVs) 
produced in vitro by either pro-inflammatory or pro-regenerative microglia on OPCs at demyelinated lesions caused by 
lysolecithin injection in the mouse corpus callosum. Immunolabelling for myelin proteins and electron microscopy 
showed that EVs released by pro-inflammatory microglia blocked remyelination, whereas EVs produced by microglia 
co-cultured with immunosuppressive mesenchymal stem cells promoted OPC recruitment and myelin repair. The 
molecular mechanisms responsible for the harmful and beneficial EV actions were dissected in primary OPC cultures. By 
exposing OPCs, cultured either alone or with astrocytes, to inflammatory EVs, we observed a blockade of OPC maturation 
only in the presence of astrocytes, implicating these cells in remyelination failure. Biochemical fractionation revealed that 
astrocytes may be converted into harmful cells by the inflammatory EV cargo, as indicated by immunohistochemical and 
qPCR analyses, whereas surface lipid components of EVs promote OPC migration and/or differentiation, linking EV 
lipids to myelin repair. Although the mechanisms through which the lipid species enhance OPC maturation still remain 
to be fully defined, we provide the first demonstration that vesicular sphingosine 1 phosphate stimulates OPC migration, 
the first fundamental step in myelin repair. From this study, microglial EVs emerge as multimodal and multitarget 
signaling mediators able to influence both OPCs and astrocytes around myelin lesions, which may be exploited to develop 
novel approaches for myelin repair not only in multiple sclerosis, but also in neurological and neuropsychiatric diseases 
characterized by demyelination. 
 
 
KEYWORDS: Microglia/ Extracellular Vesicles/ Mesenchymal stem cells/ Myelin lesion/ S1P/ Astrocytes 
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ABBREVIATIONS: 
 
Corpus callosum (CC) 
Cryo-electron microscopy (cryo-EM) 
Days post lesion (dpl) 
Diffusion Tensor Imaging (DTI) 
Dorsal root ganglion (DRG) 
Etarnecept (ETN) 
Extracellular vesicles (EVs) 
EVs from inflammatory microglia (i-EVs) 
EVs derived from IL4-treated microglia (IL4-EVs) 
EVs derived from MSC-treated microglia (MSC-EVs) 
Immunofluorescence (ICC)  
Immunohistochemistry (IHC)  
Inflammatory microglia (i-microglia) 
Lysolecithin (LPC) 
Mesenchymal stem cells (MSCs) 
Multiple sclerosis (MS) 
Oligodendrocyte precursor cells (OPCs) 
Magnetic-Activated Cell Sorting (MACS) 
Magnetic Resonance Imaging (MRI) 
Western-blot (WB)  
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INTRODUCTION 
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system characterized by secondary 
decline in myelin repair, loss of neurons and progressive disability [28] [3]. At early disease stages, successful 
remyelination is sustained by oligodendrocyte precursor cells (OPCs) [33]. In response to myelin damage, these cells, 
also called NG2-glia, proliferate and migrate to lesion sites, where they mature to new myelin-forming cells [69] [64] 
leading to restoration of rapid neurotransmission and neurological remission. During disease chronicization up to 
progressive MS, remyelination is gradually impaired, primarily due to the inability of OPCs to differentiate into 
myelinating cells, but also resulting from inefficient OPC activation and recruitment to myelin lesions [60]. At the 
cellular/molecular levels, the interplay between OPCs and microglia and other glial cells seems to play a key role in 
remyelination failure [54]. 
Microglia are the self-renewing, long-lived brain immune cells [35] whose tasks are mainly related to immune response 
and homeostasis. Guided by local environmental signals [57], microglia acquire a variety of activation states, ranging 
from protective [72] [14] to harmful [37] phenotypes participating to mechanisms of tissue repair as well as to injury. 
More than 80% of MS-specific genes identified at actively demyelinating lesions are related to microglia activation and 
T cell-mediated inflammation [66]. Moreover, interference with microglia activation limits disease progression [37], 
supporting a strong relationship between microglia activation and demyelination [28] [60]. Importantly, the negative 
impact of microglia on oligodendrocytes may occur through astrocytes, recognized players in MS immunopathology [12] 
[21], which are transformed to harmful A1 cells by inflammatory microglial mediators released from microglia (IL-1α, 
TNF and C1q) [55]. On the other hand, microglial gene expression patterns suggest favorable microglial function, such 
as phagocytosis of myelin debris and release of growth factors in acute lesions and at the active edges of chronic active 
lesions where remyelination often takes place [64] [69] [97] (reviewed in [18]) [57]. In addition, in the absence of pro-
regenerative microglia, OPC differentiation becomes less efficient, eventually resulting in impaired myelin repair [64] 
[87], whereas a switch of microglia to an anti-inflammatory phenotype promotes remyelination and ameliorates the 
clinical signs of experimental autoimmune encephalomyelitis (EAE) [100], an animal model of MS. Despite the 
demonstration of both detrimental and beneficial effects of microglia on myelin lesion, the mode(s) of action of these 
cells in aiding or inhibiting remyelination is still largely unclear.  
Extracellular vesicles (EVs), including ectosomes/microvesicles shed from the plasma membrane and exosomes 
originating from multivesicular bodies, have recently raised large interest as powerful mediators of intercellular 
communication between microglia and brain cells [90] [74] [71]. Production of microglial EVs dramatically increases 
under brain inflammation [95] [61] [22{Yang, 2018 #27] reflecting the extent of microglia activation. Following 
interaction with the recipient cells, microglia-derived EVs activate contact-mediated signaling pathways [1] [34] and/or 
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deliver genetic information [95] [25] [75], thus profoundly influencing the molecular configuration and function of the 
target cells. Specifically, microglia-derived EVs propagate an activation signal to astrocytes and to other microglia [95] 
[25]  and enhance excitatory neurotransmission [1]. However, whether or not microglial EVs play a role in the cross-talk 
between microglia and OPCs is still unknown. 
Here, we have investigated the effects on OPCs of EVs released in vitro from either pro-inflammatory or pro-regenerative 
microglia both in vivo in the lysolecithin (LPC) mouse model of focal demyelination and in vitro in primary OPC cultures. 
Although classification in inflammatory and pro-regenerative cells underestimates the complexity of microglial 
activation, such a definition provides a useful framework for investigating the impact of microglia on OPCs. To induce 
pro-regenerative traits, microglia were exposed to the classical polarizing agent IL-4 or to immunosuppressive 
mesenchymal stem cells (MSCs) [36] [101], while inflammatory state was obtained through stimulation with 
inflammatory cytokines.  
We found that EVs produced by inflammatory microglia led to blockade of OPC differentiation to myelin-forming cells. 
Conversely, EVs released from microglia exposed to MSCs promoted remyelination. Biochemical fractionation combined 
to in vitro experiments revealed a major contribution of the inflammatory cargo of EVs to blocking OPC maturation, 
while surface lipids were identified as responsible factors for the pro-myelinating action of EVs. Although the type of 
lipids driving OPC differentiation still remains to be fully defined, sphingolipid sphingosine 1 phosphate (S1P) was 
unveiled as the key molecule favoring OPC migration, the first fundamental step in the remyelination process.   
 
MATERIALS AND METHODS  
Lysolecithin-induced myelin lesions 
Demyelinating lesions were induced in the corpus callosum (CC) of adult (2.5-4 months old) and aged (8-12 months old) 
male C57BL/6 mice by stereotaxic unilateral injection of 1 μl of 2% lysolecithinto the mouse corpus callosum (CC, 
coordinates: 1.0 mm lateral, 1.0 mm rostral to Bregma and 1.5 mm deep). Three days post lesion (dpl), 2x108 EVs, 
produced by 1.5x106 microglia and dissolved in 150 µl of sterile saline, were delivered to the mice with mini-pumps 
(Alzet osmotic pumps 1007D) at the same coordinates over 4 days at 1.5 µl/h delivery rate. To limit EV degradation, 
minipumps were filled with freshly isolated EVs and implanted within a few hours. Controls were obtained with delivery 
of saline solution. To examine cell proliferation, we used the thymidine analog 5-bromo-2-deoxyuridine (BrdU), which 
is incorporated into DNA during S-phase of the cell cycle and remains in the DNA even when the cell has exited the 
active phases of the cells cycle. Mice were i.p. injected with BrdU (100 mg/kg body weight; 2 pulses 2h apart) one day 
from the start of EVs delivery. A separate group of mice received a single injection of 6.6x107 EVs, released from 0.5x106 
microglia and dissolved in 1 µl of sterile saline, at the site of lesion at 7dpl. Controls were obtained by injecting saline. 
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Mice were transcardially perfused with 4% paraformaldehyde in phosphate buffer (PB 0.1M, pH 7.4) at 4 days after mini-
pump implantation or at 3 days after acute injection and brains were post-fixed overnight and cryoprotected in 30% 
sucrose in 0.12 M PB. Surgery and perfusion were carried out under deep general anaesthesia (ketamine, 100 mg/kg, 
Ketavet, Bayern, Leverkusen, Germany; xylazine, 5 mg/kg, Rompun, Bayer, Leverkusen, Germany). All animal 
procedures were performed in accordance with the European directive (2010/63/EU) and the Italian Law for Care and 
Use of Experimental Animals (DL116/92; DL26/2014), and the studies were authorized by the Italian Ministry of Health 
(Authorization: 1112-2016PR) and the Bioethical Committee of the University of Turin.   
 
Electron microscopy of myelin lesions 
Conventional electron microscopy was carried out as in [5]. LPC-lesioned old mice injected with saline, i-EVs or MSC-
EVs were perfused transcardially with PB followed by 2% paraformaldehyde and 2.5% glutaraldehyde in PB. The brain 
was removed and post-fixed overnight at 4°C in the same fixative. Vibratome sagittal sections (250 μm thick) were cut, 
and post-fixed with 1% osmium tetroxide for 1h at 4°C, then stained with uranyl acetate replacement stain (Electron 
Microscopy Sciences, USA). After dehydration in ethanol, samples were cleared in propylene oxide and embedded in 
Araldite (Fluka, Saint Louis, USA). Semithin sections (1 μm thick) were obtained at the ultramicrotome (Ultracut UCT, 
Leica, Wetzlar, Germany), stained with 1% toluidine blue and 2% borate in distilled water and then observed under a 
light microscope for precise lesion location. Ultrathin sections (70-100 nm) were examined under a transmission electron 
microscope (JEOL, JEM-1010, Tokyo, Japan) equipped with a Mega-View-III digital camera and a Soft-Imaging-System 
(SIS, Münster, Germany) for computerized acquisition of the images. Profiles of microglia, astrocytes, oligodendrocytes 
and myelinated axons were identified according to well established criteria [78]. Microglia were distinguished by their 
specific ultrastructural features including frequent stretches of endoplasmic reticulum and a condensed, electron-dense 
cytoplasm [7] [89]. In the core of the lesion, electron micrographs were taken at 25K magnification and ImageJ software 
(https://imagej.nih.gov/ij/) was used to measure the proportion of myelinated axons (on at least 150 axons/animal) and 
perform the measurements needed to obtain G-ratios, the ratios of the axonal diameter (d white, Fig. 4k) to the outer fiber 
diameter including the myelin sheath (D yellow, Fig. 4k), of at least 50 myelinated axons/animal. Quantifications were 
performed on three mice (8-12 months old) per experimental condition. 
 
Immunohistochemistry 
Brains were processed according to standard immunohistochemical procedures [9]. They were cut into 30-µm-thick 
coronal sections, collected in PBS and stained with the antibodies reported in the table I. OPCs were labelled by anti-
NG2 antibodies while more mature cells were detected by anti-CC1 serum. Anti-Olig2 and anti-Sox10 stained the whole 
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oligodendrocyte lineage. Anti-MBP antibodies labelled myelin. To follow cell proliferation, we used anti-BrdU. DAPI or 
Hoechst33258 were used to label nuclei. Anti-GFAP, anti-PTX3 and anti-C3 were used to label astrocytes, Iba-1 to reveal 
microglia. Sections were incubated overnight with primary antibodies at 4°C in PBS with 1.5% donkey serum, 2% bovine 
serum albumin and 0.5% Triton X-100 Sections were then exposed for 2 h at room temperature to secondary anti-rabbit, 
anti-chicken antibodies conjugated with Alexa Fluor 488 or anti-rabbit antibodies conjugated with Alexa Fluor 546 
(1:500; Invitrogen, Waltham, MA USA), anti-mouse, anti rabbit antibodies conjugated with Cy3 (1:500; Jackson 
ImmunoResearch, West Grove, PA, USA), anti-goat antibodies conjugated with Alexa Fluor 649 (1:500; Invitrogen) or 
anti-mouse antibodies conjugated with Cy5 (1:500; Jackson ImmunoResearch). Double staining with rabbit anti-GFAP 
and rabbit anti-PTX3/anti-C3 was performed using the High Sensitivity Tyramide-Rhodaminate Signal Amplification kit 
(Perkin-Elmer, Monza, Italy) following the manufacturer’s instructions. Following counterstaining with 4,6-diamidino-
2-phenylindole (DAPI) (Sigma-Aldrich Co., St. Louis,MO, United States) or Hoechst 33258 (Life Technologies, Monza, 
Italy) to label nuclei, slides were coverslipped with Mowiol (Millipore, Burlington, MA,USA) or with a fluorescent 
mounting medium from Dako (Milan, Italy). All images were collected using a Nikon Eclipse 90i confocal microscope 
(Nikon, Melville, NY), or using a Zeiss LSM 800 confocal microscope (Carl Zeiss S.p.A, Milano, Italy). Adobe 
Photoshop 6.0 (Adobe Systems) was used to adjust image contrast and assemble the final plates. Measurements were 
derived from at least three sections per mice. Three to five animals were analyzed per each time point or experimental 
condition. Image analysis was performed with the Image J software to quantify the proportion of NG2 or MBP-stained 
pixels throughout the entire lesioned area in each section [64] [53] [46].  Density of oligodendroglial, proliferative cells 
and PTX3- and C3-positive astrocytes in the lesion was calculated as number of cells/mm2, using the ImageJ software.  
 
Table I: List of primary antibodies used for immunohistochemistry (IHC), immunofluorescence (ICC) and western-blot 
(WB) analyses.  
 
Antibody Host Supplier IHC dilution 
ICC 
dilution 
WB 
dilution 
anti-NG2 Rabbit Millipore (Burlington, MA,USA) 1:200 1:100  
anti-CC1 Mouse Millipore (Burlington, MA, USA) 1:1500   
anti-CNPase Rabbit SantaCruz (Dallas, Texas)   1:250 
anti-Olig2 Rabbit Millipore (Burlington, MA,USA) 1:500 1:300  
anti-SOX-10 Goat SantaCruz  (Dallas, Texas) 1:200   
anti-MBP Rat AbD Serotec (Oxford, UK)  1:200  
anti-MBP Rat Covance (Princeton, NJ) 1:1000   
anti-MBP Rat Millipore (Burlington, MA, USA)  1:200 1:500 
anti-BrdU Rat Abcam (Cambridge, UK ) 1:500   
anti-pentraxin3 Rabbit 
home-made generated as 
previously described, [10] 
1:250   
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Magnetic Resonance Imaging (MRI) 
In vivo MRI was performed using a 7 Tesla scanner (Bruker-Biospin) equipped with a radiofrequency coil for mouse. 
Mice were anesthetized with an intramuscular injection of Ketamine (100 mg/kg; Ketavet, Bayern, Leverkusen, Germany) 
mixed with xylazine (5 mg/kg; Rompun, Bayer, Leverkusen, Germany). High Resolution coronal and sagittal images, T2 
weighted (TR/TE=3000/48ms, slice thickness=0.7 mm, pixel=78x80 µm) were acquired to localize lesions in the corpus 
callosum. Diffusion Tensor Imaging (DTI: 30 directions, b=1000 sec/mm2) was also used to measure water molecule 
diffusivity across white matter fibers to further characterize CC lesions.  
 
Primary cultures 
Mixed glial cell cultures, containing both astrocytes and microglia, were established from rat Sprague–Dawley pups (P2) 
(Charles River, Lecco, Italy) and maintained for 10 days in the presence of South American fetal bovine serum (Life 
anti-C3 Rabbit Dako (Milan, Italy) 1:250   
Anti-GFAP Rabbit Dako (Milan, Italy) 
1:30000 with 
amplification 
kit 
  
Anti-GFAP Mouse Sigma-Aldrich (Milan, Italy)  1:100  
anti- Neurofilaments 
(SMI32) 
mouse Cell Signaling (Beverly, MA)  1:500  
anti- Neurofilaments 
(SMI31) 
mouse Cell Signaling (Beverly, MA)  1:500  
anti-α-tub mouse Sigma-Aldrich   1:2000 
Anti-GSTpi rabbit 
MBL International Corporation 
(Sunnyvale, CA) 
  1:500 
Anti-GPR17 rabbit 
home-made generated as 
previously described, Ciana 2006 
  
 
1:1000 
Anti-GPR17 rabbit 
Cayman Chemical (Michigan, 
USA) 
 1:100 
 
 
Anti-GFP Chicken AVES Labs 1:700 1:1400  
Anti-GFP Rabbit Life Technologies (Monza, Italy)   1:3000 
Anti-Iba1 Rabbit Wako Chemicals (Richmond, VA) 1:1000   
4′,6-diamidino-2-
phenylindole DAPI 
 Fluka (Buche, Switzerland) 1:1000   
DAPI  
Molecular Probes (Life 
Technologies,  Monza, Italy) 
 1:20.000  
Hoechst 33258  Life Technologies (Monza, Italy) 1:50000 1:10000  
Anti-Alix Rabbit Covalab (Villeurbanne, France)   1:500 
Anti-Flotilin 2 Mouse BD transduction (San Jose, CA)   1:1000 
Anti-GAPDH Rabbit 
Synaptic Systems (Goettingen 
Germany) 
  1:1000 
Anti-GS28 Mouse BD transduction (San Jose, CA)   1:1000 
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Technologies, Monza, Italy) that optimizes microglia expansion or fetal bovine serum (EuroClone, Milan, Italy) which 
favors OPC proliferation.  
Microglia. Microglia were harvested by orbital shaking for 40 min at 1,300 r.p.m. and re-plated on poly-L-ornithine -
coated tissue culture dishes (50 μg/mL, Sigma-Aldrich, Milan, Italy). To minimize the activation, pure microglia (> 98%, 
[75] were kept for 24 hrs in low-serum (1%) medium. Cells were then stimulated with a cocktail of Th1 cytokines, i.e. 20 
ng/ml IL-1β (Peprotech, Milan, Italy), 20 ng/ml TNF-α (Peprotech, Milan, Italy) and 25 ng/mL IFN-ɣ (Sigma Aldrich, 
Milan, Italy), or with 20 ng/ml IL-4 for 48 hrs (R&D, Milan, Italy). In addition, microglia were co-cultured in transwell 
with MSCs at a microglia-to-MSCs ratio of 1:1 for 48 hrs in the presence of Th1 cytokines. MSCs were plated on the 
filter of the upper chamber and microglia in the lower chamber of the transwell. At the end of treatment, MSCs were 
removed, microglia were washed and stimulated with ATP to increase EV production [75]. To obtain GFP-labelled EVs, 
microglia were established from GFP-transgenic rats expressing GFP under the chicken beta actin promoter [68]. Indeed, 
GFP is included in EVs released by GFP-positive microglia (Suppl. Fig. 3h, Online resource).  
OPCs. After microglia removal, OPCs growing on top of astrocyte monolayer were isolated by shaking cells on an orbital 
shaker at 200 rpm for 3h and incubated on an uncoated Petri dish for 1hr to further eliminate microglia. Pure OPCs (> 
95% [32] were seeded onto poly-D,L-ornithine-coated glass coverslips or plates (50 μg/mL, Sigma-Aldrich, Milan, Italy) 
in Neurobasal (Life Technologies, Monza, Italy) supplemented with 2% B27 (Life Technologies, Monza, Italy), 2 mM 
L-glutamine (EuroClone, Milan, Italy), 10 ng/mL human platelet-derived growth factor BB (Sigma-Aldrich, Milan, Italy), 
and 10 ng/mL human basic fibroblast growth factor (Space Import Export, Milan, Italy), to promote proliferation 
(proliferating medium). After 3 days, cells were either detached with accutase (Millipore, Burlington, MA, USA) and 
used for migration assay, or switched to a Neurobasal medium lacking growth factors and supplemented with 
triiodothyronine T3 (10 ng/ml, Sigma Aldrich, Milan, Italy) to allow differentiation (differentiating medium).  
Dorsal root ganglion (DRG)-OPC co-cultures. DRG-OPC co-cultures were prepared according to a previously 
described protocol [31]. Briefly, DRG from E14.5 mouse embryos were plucked off from spinal cord, put in culture (1 
DRG/coverslip) in Neurobasal supplemented with B27 in the presence of nerve growth factor (NGF) (100 ng/ml; Harlan, 
Milan, Italy) and cycled with fluorodeoxyuridine (10 μM; Sigma Aldrich, Milan, Italy) to eliminate all non-neuronal cells. 
After 20 days, when neurites were well extended radially from DRG explants, 35x103 OPCs were added to each DRG in 
culture and kept in Minimum essential media MEM (Life Technologies Monza, Italy) supplemented with glucose (4 g/L; 
Sigma Aldrich, Milan, Italy), 10% FBS and 2 mM L-glutamine (EuroClone, Milan, Italy). Myelination was induced the 
following day by the addition of recombinant chimeric tyrosine kinase receptor TrkA Fc (1 μg/ml; Sigma Aldrich, Milan, 
Italy) to the culture medium. 
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Astrocyte-OPC co-cultures. Purified astrocytes were isolated from P2 rat whole brains by magnetic-activated cell 
sorting (MACS) (Miltenyi Biotec, Bergisch Gladbach, Germany) with anti-GLAST (ACSA 1) MicroBeads according to 
the manufacturer's instructions. After 1 week, OPCs were plated on top of astrocytes at an astrocyte-to-OPC ratio of 1:1. 
In a set of experiments astrocytes were isolated from P2 mouse whole brains and cultured alone for qPCR analysis of 
specific markers for A1 and A2 astrocytes. 
MSCs. MSCs were prepared and expanded as described previously [102]. Briefly, marrow cells were flushed out from 
tibias and femurs of 6-8-week-old C57BL/6J mice and cultured in plastic plates as adherent cells using murine Mesencult 
as medium (Stem Cell Technologies, Vancouver, BC, Canada). Medium was refreshed every 3 days until cells reached 
80% confluence. Following treatment with 0.05% trypsin solution containing 0.02% EDTA (Euroclone, Milan, Italy), the 
cells were plated in 75 cm2 flask at the density of 4x105 cells. Mature MSCs, obtained after four to five passages in culture, 
were defined by the expression of CD9, Sca-1, CD73, and CD44 and the lack of the hematopoietic markers CD45, CD34, 
and CD11b on their surface, and their immunosuppressive activity was verified in T-cell proliferation assays [102].  
 
RNA isolation and qRT-PCR 
Total RNA was isolated from rat primary microglia using Direct-zol™ RNA MiniPrep (Zymo Research, Irvine CA, USA) 
following the manufacturer’s protocol. cDNA synthesis was performed using High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City CA, USA) and Random Hexamers as primer. The resulting cDNAs were amplified 
using TaqMan® Gene Expression Assay (Applied Biosystems, Foster City CA, USA) using QuantStudio™5 
(ThermoFisher Scientific, Waltham MA, USA) real-time PCR system. The mRNA expression was normalized to the label 
of Rpl13 (Ribosomal Protein L13) mRNA. Data obtained were quantified using the 2-ΔΔCT method [56]. Q-PCR for A1 
and A2 markers was performed on murine astrocytes with the Luna Universal Probe qPCR Master Mix (M3004S, New 
England Biolabs) using the StepOneTM Plus Real-Time PCR System (Life Technologies, Monza, Italy). The expression 
of selected genes was normalized to the expression of the housekeeping gene β-actin. The list of primers used can be 
found in Table II. 
 
Table II: List of gene expression assays for qPCR. 
 
Gene Symbol Name Taqman Assay 
Arg 1 Arginase 1 Rn00691090_m1 
C1q Complement C1q Rn01519903_m1 
IL1-a Interleukin 1 Alpha Rn00566700_m1 
IL1-β Interleukin 1 Beta Rn00580432_m1 
iNOS Nitric Oxide Synthase 2 Rn00561646_m1 
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Rpl13a Ribosomal Protein L13 Rn00821946_g1 
Socs-3 Suppressor Of Cytokine Signaling 3 Rn00585674_s1 
TNF-α Tumor Necrosis Factor Rn99999017_m1       
Amigo 2 Adhesion Molecule With Ig Like Domain 2 04688058001 
β-actin Actin Beta 04688635001 
CD14 Monocyte Differentiation Antigen CD14 04687574001 
Ptx3 Pentraxin 3 04686993001 
Tm4sf1 Transmembrane 4 L Six Family Member 1 04687990001 
Serping1 Serpin Family G Member 1 04689011001 
 
EV isolation and quantification 
EVs were isolated from microglia exposed to Th1 cytokine cocktail (i-EVs), IL-4 (IL4-EVs) or MSC (MSC-EVs). To 
isolate EVs, polarized microglia were stimulated with 1 mM ATP for 30 min in KRH (125 mM NaCl, 5 mM KCl, 1.2 
mM MgSO4, 1.2 mM KH2PO, 2 mM CaCl2, 6 mM D-glucose, and 25 mM HEPES/NaOH, pH 7.4). The culture 
supernatant was collected and released EVs were pelleted at 100k g after pre-clearing from cells and debris at 300 g, as 
previously described [34]. In some experiments, an ectosome-enriched fraction was pelleted at 10k g. EV pellets were 
resuspended and used immediately after isolation. The number and dimension of EVs were assessed using NanoSight 
NS300 (NanoSight, UK) configured with a 488 nm laser and SCMOS camera. Videos were collected and analyzed using 
the NTA-software (version 2.3), with the minimal expected particle size, minimum track length, and blue setting, all set 
to automatic. Camera shutter speed was fixed at 15 ms and camera gain was set to 300. Room temperature was ranging 
from 25°C to 28°C. EV pellets were re-suspended in 800 μl of 0.1 μm-filtered sterile KRH and four recordings of 30 
seconds were performed for each sample. 
EVs were destroyed by hypo-osmotic stress and re-pelleted to remove their luminal cargo as previously described [34]. 
For biochemical fractionation of EVs, total lipids were extracted with 2:1 (by volume) of chloroform and methanol. The 
lipid fraction was evaporated under a nitrogen stream, dried for 1h at 50°C and resuspended in PBS at 40°C in order to 
obtain multilamellar vesicles. Small unilamellar vesicles were obtained by sonicating multilamellar vesicles, following 
the procedure of [4].  
 
Quantification of sphingolipid content in EVs 
[3H] Sphingosine ([3H]Sph) was stocked in absolute ethanol. For the quantification of sphingolipid content in EVs, 1x106 
microglia were pulsed with [3H]Sph (0.3 µCi/ml) for 24h followed by a 48h chase in order to obtain a [3H]GM3/[3H]SM 
ratio corresponding to that of endogenous compounds (data not shown), an index for a steady-state labeling of cell 
sphingolipids [96]. At the end of the chase, microglia were stimulated with ATP, EVs were pelleted and the cells were 
washed twice with PBS at 4°C and harvested. Total lipids were extracted from both EVs and cells and processed as 
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previously described [79] [80]. The organic phase and the aqueous phase were analyzed by high performance thin layer 
chromatography (HPTLC) using chloroform/methanol/water (55:20:3 by volume) and butanol/acetic acid/water (3:1:1 by 
volume) as the solvent systems. 
 
Raman Spectroscopy 
The Raman analysis was performed following a previously described protocol [40]. Briefly, freshly isolated EVs were 
laid on a calcium fluoride slide and allowed to air dry. All of the measurements were performed with a Raman 
microspectroscope (LabRAM Aramis, Horiba Jobin Yvon S.A.S, Lille, France) equipped with a laser line operating at 
532 nm and a Peltier-cooled CCD detector. Acquisitions were performed with 50X objective (NA 0.75, Olympus, Tokyo, 
Japan), 1800 grooves/mm diffraction grating, 400 μm entrance slit, and confocal mode (600 μm pinhole) in the spectral 
ranges 600–1800 cm−1 and 2600–3200 cm−1. Accumulation times were 2x30s per spectrum. Silicon reference sample was 
used for the instrument calibration. At least 30 independent replicates of the Raman spectra were obtained for every EV 
type. After acquisition, polynomial baseline correction and unit vector normalization were performed before the 
multivariate statistical analysis. 
 
OPC migration assay  
Migration of OPCs was performed in Boyden chambers (8 μm pore size filter; Constar, Corning, NY, USA) as previously 
described [11]. Briefly, the chamber was nested inside the well of 24-well plates and 5x104 OPCs were seeded in the top 
of each insert with 200 μl of neurobasal medium. The bottom well was filled with 600 μl of medium containing EVs 
released from 1x105 microglia (~4x108 EVs/ml). The chemotactic agent sphingosine-1 phosphate (S1P) (100 nM) was 
used as positive control. After 16h, non-migrated cells were removed from the top compartment with a cotton swab, 
whereas cells that had migrated to the lower side of the filter were fixed with 4% paraformaldehyde and stained with 
Hoechst33258 (Life Technologies, Monza, Italy). Images were acquired at 20X magnification under an inverted 
fluorescence microscope (200M; Zeiss, Oberkochen, Germany) and cells were counted using ImageJ cell counter plugin 
in 45 random fields per well. All conditions were run in triplicate. Data are expressed as a percentage of basal migration, 
that is the migration of OPCs without chemoattractant.  
 
EV delivery by optical manipulation 
An IR laser beam (1064 nm, CW) for trapping was coupled into the optical path of an inverted microscope (Axiovert 
200M, Zeiss, Oberkochen, Germany) through the right port of the microscope. The trapping beam was directed to the 
microscope lens (Zeiss 63X, NA 1.4) by the corresponding port mirror (100%) and the tube lens. Optical trapping and 
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manipulation of EVs was performed following the approach previously described [73]. Immediately before recording, 
EVs were added in the temperature-controlled recording chamber, where OPCs plated on glass coverslips were 
maintained in 400 μl of Neurobasal medium with B27. As soon as an EV appeared in the recording field, it was trapped 
and positioned on a selected OPC by moving the cell stage horizontally and the microscope lens axially. After about 30s 
from initial contact, the laser was switched off to prove EV-OPC interaction, as previously described [73]. During the 
experiments, OPCs were live-imaged with a spinning disk confocal microscope (UltraVIEW acquisition system, Perkin 
Elmer Waltham, MA, United States) using a digital camera (High Sensitivity USB 3.0 CMOS Camera 1280X1024 Global 
Shutter Monochrome Sensor, Thorlabs, Newton, NJ, United States) at a frame rate of 2 Hz. 
 
OPC proliferation assay 
One day after plating on glass coverslips, OPCs were co-exposed to EVs derived from twice as many microglia (~2x107 
EVs/500 µl) and to the thymidine analog EdU (Click-iT® EdU Assay, Life Technologies, Monza, Italy) for 24h in 
proliferating medium. Cells were fixed with 4% paraformaldehyde and stained for EdU following the manufacturer’s 
instructions. Coverslips were then incubated with DAPI (1:20000, Molecular Probes, Life Technologies) to reveal total 
nuclei and mounted with a fluorescent mounting medium (Dako, Milan, Italy). 40-50 fields per coverslip were imaged at 
20X magnification under an inverted fluorescence microscope (200M Zeiss, Oberkochen, Germany) connected to a PC 
computer equipped with the Axiovision software (Zeiss). OPC proliferation was assessed by quantifying EdU-DAPI 
double positive nuclei in at least three coverslips/condition, using ImageJ cell counter plugin. Cells with nuclei larger 
than 15 microns, belonging to astrocytes occasionally present in the cultures, were excluded from the analysis. 
 
OPC differentiation assay 
OPCs were kept for 3 days in proliferating medium, shifted to differentiating medium for 24h and then exposed to EVs 
for 48h (2x107 EVs/500 µl). Cells were fixed and labelled with anti-G Protein-Coupled Receptor 17 (GPR17) and anti-
MBP (table I) in Goat Serum Dilution Buffer (GSDB; 450 mM NaCl, 20 mM sodium phosphate buffer, pH 7.4, 15% goat 
serum, 0.3% Triton X-100), followed by secondary antibodies conjugated to Alexa Fluor 555 or Alexa Fluor 488 (1:200; 
Molecular Probes, Life Technologies). Differentiation towards mature oligodendrocytes was determined by counting 
MBP+ cells over total DAPI+ cells in 35-45 fields per coverslip with ImageJ software. GPR17 staining was used to reveal 
immature oligodendrocytes, the most abundant oligodendrocyte population after 3 day in differentiating medium. 
 
OPC myelination assay 
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OPC-DRG co-cultures were kept in 1 μg/ml TrkA-Fc for 5 days and then exposed to EVs for 11 days (fresh EVs, 2x107 
EVs/500 µl, were added at day in vitro (DIV5, DIV8 and DIV12). Cells were fixed at DIV16 with paraformaldehyde and 
labelled with anti-MBP and anti-high-molecular-weight neurofilaments (NF) antibodies (SMI31 and SMI32 in table I) in 
GSDB, followed by secondary antibodies conjugated to Alexa Fluor 555 or Alexa Fluor 488 (1:600; Molecular Probes, 
Life Technologies). Nuclei were labelled with DAPI. Coverslips were mounted with a fluorescent mounting medium 
(Dako, Milan, Italy). For the co-culture analysis, stacks of images of MBP- and SMI31- and SMI32-positive cells were 
taken under confocal microscope at 40X magnification (at 6 fields/coverslip) and the ZEISS LSM Image Browser was 
utilized to automate quantification of the myelination index. Images in the stack were merged at each level and pixels 
overlapping in the red and green fields above a predefined threshold intensity value were highlighted in white. The amount 
of myelin per axon (myelination index) was calculated as the ratio between the white pixel and the green pixel areas. 
 
Western blot analysis  
OPCs were lysed with a buffer containing 1% sodium dodecyl sulfate (SDS), 10 mM HEPES, 2 mM EDTA pH 7.4. A 
modified version of the Laemmli buffer (20 mM Tris pH 6.8, 2 mM EDTA, 2% SDS, 10% glycerol, 2% β-
mercaptoethanol, 0.01% bromophenol blue) was then added to a final 1X concentration and proteins were separated by 
electrophoresis, blotted on nitrocellulose membrane filters and probed using the using the primary antibodies reported in 
the table I  and the HRP-conjugated secondary antibodies (goat anti-rat 1:1000, goat anti-rabbit 1:4000 and goat anti-
mouse 1:2000; Sigma Aldrich, Milan, Italy). Photographic development was by chemiluminescence (ECL, GE 
Healthcare) according to the manufacturer’s instructions. Densitometric analysis of the protein bands was performed with 
ImageJ software. Band intensities were measured as integrated density volumes (IDV) and expressed as percentage of 
control lane values. 
 
ELISA 
The concentration of IL-1a or C1q or TNF-α in microglial cells or EVs were quantified using a solid-phase sandwich 
ELISA (enzyme-linked immunosorbent assay) kit following the manufacturer’s protocol (Rat IL-1a ELISA kit, Invitrogen 
Waltham, MA USA, BMS627; Rat TNF-α ELISA kit, Invitrogen Waltham, MA USA, BMS622, Rat C1q ELISA kit, 
Novus Biologicals Centennial, CO, USA, NBP2-74988). IL-1a or C1q or TNF-α content in the cells was determined after 
cell lysis with RIPA Buffer (Sigma Aldrich, Milan, Italy) whereas inside EVs after detergent permeabilization with 0.6% 
Triton X-100 (Sigma Aldrich, Milan, Italy) in presence of protease inhibitors (1:1000, Sigma Aldrich, Milan, Italy). 
Sample absorbance was measured with a spectrophotometric system (1420 Multilabel Counter Victor 2; Wallac) at 450 
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nm at 10 Hz. The amount of IL-1a, C1q or TNF-α in EVs was estimated on the basis of a standard curve in the presence 
0.6% Triton X-100. 
 
Cryo-electron microscopy 
Cryo-EM allows imaging of samples without the addition of any heavy metals or fixatives, which might cause artefacts, 
with the drawback of yielding a lower contrast. The sample is frozen so rapidly that the water vitrifies forming no ordered 
crystals, and the native structure of the sample is preserved [26] [70]. Freshly prepared vesicles resuspended in saline 
were plunge frozen in liquid propane using a Vitrobot Mark IV (ThermoFisher Scientific, Oregon, USA). 
 
Drugs and reagents 
S-FTY720-Vinylphosphonate (kind gift from Prof. Robert Bittman) was dissolved in fatty acid free bovine serum albumin 
(1 mM in PBS). S1P (Enzo Biochem. Inc, Farmingdale, NY) was dissolved in fatty acid free bovine serum albumin (4 
mg/ml in distilled water). Stock solutions were diluted in fresh Krebs-Ringer solution.  
 
Statistical analysis 
All data are presented as mean ± SEM from the indicated number of experiments “N”. Statistical analysis was performed 
using SigmaStat 3.5 software (SigmaStat software, San Jose, California). After testing data for normal distribution, the 
appropriate statistical test was used and the overall p-value indicated in the figure legends. Group differences were 
considered significant when P was <0.05, indicated by an asterisk; those at P was <0.01 are indicated by double asterisks; 
those at P<0.001 are indicated by triple asterisks. For the Raman spectra, Principal Component Analysis and Linear 
Discriminant Analysis (PCA-LDA) were performed by means of Origin2018 (OriginLab, Northampton, MA, USA). To 
test the sensitivity, specificity and accuracy of the classification model to distinguish the EV phenotype by the overall 
biochemical composition, leave-one-out cross-validation was used.  
 
RESULTS  
EVs bud at the surface of microglia infiltrating the myelin lesion  
Injection of the detergent lysolecithin into the mouse corpus callosum (CC) causes a demyelinating injury within 4 days 
which spontaneously recovers over time, offering a robust approach to study remyelination [69] [64]. In this model, 
infiltration and activation of macrophage/microglia were shown to be important for OPC migration and successful 
differentiation into myelin-forming cells [50] [64].  
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Ten days after the lesion (dpl), through high-resolution EM analysis, we found cells with the ultrastructural features of 
microglia (Fig.1a) along with astrocytes and oligodendrocytes (Fig.1b) at the lesion site. Importantly, microglia exhibited 
condensed, electron-dense cytoplasm and nucleoplasm, resembling “dark” microglia, a recently described phenotype of 
reactive cells [7] [27], characterized by pronounced chromatin remodeling, which is indicative of altered gene expression. 
Although the narrow conformation of the extracellular space commonly constrains EV visualization, we observed a dark 
microglial cell infiltrating the lesion, with several blebs at the cell surface and surrounded by putative membrane vesicles 
in the pericellular space (Fig.1c), suggesting intense EV production. This evidence prompted us to investigate the role of 
EVs in the interplay between reactive microglia and OPCs at lesion sites. Inhibiting endogenous EV production without 
interfering with the remyelination process is challenging, given that most effective pharmacological or genetic inhibitors 
of EV biogenesis interfere with sphingolipid metabolism [94]. We therefore analyzed the action of exogenous EVs 
produced in vitro by polarized microglia. 
 
Distinct phenotypic signatures of EVs released by either pro-inflammatory or pro-regenerative microglia 
Primary rat microglia were maintained in the absence of stimuli (NS), under inflammatory (Th1 cytokine cocktail) or pro-
regenerative (IL-4) conditions for 48h. They were also co-cultured with MSCs in transwell system in the presence of 
inflammatory cytokines (Fig.2a) to drive pro-regenerative functions [36] [101]. Gene expression analysis revealed distinct 
patterns of phenotypic marker expression in the four conditions. Despite common upregulation of pro-regenerative 
arginase 1 (Arg1) in MSC-treated and IL-4-treated microglia, the former ones maintained pro-inflammatory traits 
(elevated IL-1a, C1q, IL-1β and iNOS) and selectively upregulated a few genes, including Suppressor of cytokine 
signaling 3 (Socs-3), a gene involved in negative regulation of cytokines and Choline Phosphotransferase 1 (Chpt1), an 
enzyme involved in phosphatidylcholine synthesis (Fig. 2b). 
Non-stimulated (NS) microglia and polarized cells were exposed to ATP for 30 min to promote EV release, and EVs were 
isolated by ultracentrifugation at 100k g after pre-clearing of cell supernatants from cells and debris [34]. Cryo-electron 
microscopy (cryo-EM) analysis revealed that most EVs from NS microglia consisted of a single lipid bilayer (Fig. 2c, c’’, 
c’’’; 88%) and were rounded in shape (Fig. 2c-c’’; 66%), but were very heterogeneous in size, ranging from 15 to 1,070 
nm in diameter (mean diameter=81.14±9.11 nm). A subpopulation of EVs contained one or more vesicles in their lumen 
(10%; Fig. 2c’), or were coated on their surface (Fig. 2c’’; 15%), likely due to the presence of transmembrane or 
membrane-associated proteins. According to our previous evidence [95] [34], cryo-EM excluded contamination with 
apoptotic bodies or intracellular organelles derived from damaged cells. Nanosight Tracking Analysis showed no major 
changes in total EV production from reactive microglia compared to NS cells (Fig.2d). Conversely, clear differences in 
the molecular composition of EVs derived from polarized microglia were revealed by Raman spectroscopy (Fig. 2e), a 
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sensitive optical technique already proven to provide information on the chemical content of EVs [85] [88] [51] [40] [39]. 
Beside the characteristic bands of proteins and nucleic acids (proteins: Amide I 1600–1690 cm−1, Amide III 1200–1300 
cm−1; nucleic acids: 720–820 cm−1), main differences were identified in the spectral intervals that can be attributed to 
lipid components (mainly 2700–3200 cm−1). In particular, EVs derived from non-stimulated and polarized microglia 
showed differences in the relative intensities of peaks attributable to cholesterol and cholesterol ester (700; 1127; 1440 
cm−1) and in peaks corresponding to the CH2 deformations (around 1300 cm−1) and CH, CH2, and CH3 bonds (in the 
spectral range 2600–3200 cm−1), which are known to be related to lipids [43]. Despite such similarities, significant 
differences among IL4-EVs and MSC-EVs spectra were highlighted by linear discrimination analysis, suggesting that the 
two types of EVs carry distinct cargoes beyond common molecules, thus reflecting the distinct phenotypes of donor cells. 
The classification model PCA-LDA demonstrated that RS can distinguish the microglia phenotypes of the EV source 
with an overall accuracy of 91.7% and an error rate of 18.24% after cross-validation. The error rate was reduced to 10.16% 
when analyzing spectra from broken EVs, busted by hypo-osmotic shock [34], and re-pelleted to remove soluble 
components supporting the major contribution of membrane components in the spectral differences between the EV 
subtypes (Suppl. Fig. 1, Online Resource). 
 
Microglia-derived EVs display a dual action on the oligodendroglial response to focal demyelinating lesions 
We first examined the action of EVs produced by inflammatory microglia (i-EVs) and pro-regenerative cells (IL4-EVs 
and MSC-EVs) on the early response to demyelination (3 dpl), during the phase of OPC recruitment [64] [48] [41]. EVs 
produced by 1.5 million cells (~2-3x108) were delivered to focal myelin lesion via pre-filled Alzet mini-pumps for 4 days 
(at 2X106 EVs/h). EVs were still present in the mini-pumps 3 days after re-suspension, albeit the concentration was 
reduced by ~30%, as measured by Nanosight Tracking Analysis (EV concentration= 2.80 x 108± 0.19 at day 0; 2.60 x 
108 ± 0.13 at day 1; 1.90 x 108 ± 0.08 at day 3).  Mice received BrdU twice (2h apart), at 4 dpl, to monitor cell proliferation 
and the tissue was analyzed at the end of the treatment (7dpl) (Fig. 3a).  
Quantification of BrdU+ cells showed that all EV types significantly increased cell proliferation in the lesion area 
compared to saline-injected controls (Fig. 3b). However, we found almost no impact of EVs on the proliferation of Olig2+ 
oligodendroglial cells (Fig. 3c), indicating that other brain cells proliferate in response to EVs. While not increasing 
oligodendrocyte proliferation, both IL4-EVs and MSC-EVs increased the density of oligodendroglial cells positive for 
the transcription factors Sox10 in the lesion area, suggesting enhanced migration of OPCs to the lesion site (Fig. 3d, e). 
Staining for myelin protein MBP showed that both IL4-EVs and MSC-EVs promoted the full differentiation of 
oligodendrocytes, as shown by increased MBP+ labelling in the lesioned area (Fig. 3f, g). This maturation effect was 
accompanied by a decrease in immature NG2+ OPCs (NG2+/Sox10+ cells) (Fig. 3e) and an increase in density of 
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oligodendrocytes undergoing differentiation (NG2-Sox10+ cell density: saline, 721.3 ± 88.64; i-EVs, 562.0 ± 40.31; IL4-
EVs, 755.1 ± 82.13; MSC-EVs, 1080 ±  98.97; One Way ANOVA main effect of treatment p=0,0114 with Holm-Sidak's 
multiple comparisons test) upon MSC-EVs delivery. By contrast, the fraction of MBP staining in the lesioned area 
decreased upon i-EV infusion (Fig. 3f, g) while the tissue exhibited a significant increase in NG2 staining (Fig. 3h, i). 
Accordingly, the percentage of NG2+/Sox10+ early progenitors increased in comparison to controls (Fig. 3e). 
Overall, these data indicate that prolonged delivery of EVs produced by beneficial microglia, especially MSC-treated 
microglia, promotes the accumulation of oligodendrocytes at the lesion site and enhances remyelination, whereas i-EVs 
injection inhibits OPC maturation. 
To further assess the impact of EVs on OPC differentiation, MSC-EVs and i-EVs (7x107 EVs, corresponding to about 
one third of EVs delivered over 4 days via the minipump) were delivered to LPC-treated mice by a single injection at 7 
dpl, when OPCs become post-mitotic and progress toward differentiation into myelin-sheath forming oligodendrocytes 
[64]. The remyelination process was analyzed at 10 dpl in both young (2.5-4 months old) and aged (8-12 months old) 
mice (Fig. 4a), in which remyelination occurs more slowly [83] [84] [44] [82]. MRI analysis showed that this time-
window is optimal to study remyelination in our experimental setting. Indeed, at 5-6 dpl, before EV treatment, hyper-
intense signal on T2-weighted MR images indicated clear myelin lesions in almost the entire CC, whereas at 10 dpl CC 
signal returned hypointense almost similar to healthy controls, suggesting fast recovery (Suppl. Fig. 2, Online Resource). 
Remyelination of CC was also observed by Diffusion Tensor Imaging (DTI), showing considerably increased diffusivity 
perpendicular to white matter fibers at 5 dpl, and return to normal values at 10 dpl (Suppl. Fig. 2, Online Resource).  
The presence of EVs at the lesion site was verified in mice injected with GFP-labelled EVs produced by GFP-expressing 
microglia. Twenty minutes after a single injection, GFP-EVs were localized within the lesion evidenced by DAPI staining 
(Suppl. Figure 3a-d’, Online Resource). Immunolabelling for the lineage markers Iba1, S100β or NG2 and 3D 
reconstruction by Imaris showed GFP-EVs inside microglia/macrophages (Suppl Fig. 3e-e’’’’, Online Resource), 
astrocytes (Suppl Fig 3f-f’’, Online Resource) or NG2+ cells (Suppl Fig 3g-g’’’, Online Resource). 60 min after injection, 
GFP-EVs were no longer visible in proximity or away from the injury (not shown).   Despite being injected in a single-
pulse and in lower amounts compared to the prolonged treatment, both i-EVs and MSC-EVs had a strong impact on 
oligodendrocytes during the phase of OPC differentiation. In aged mice, i-EVs produced a significant decrease in MBP 
staining (Fig. 4c-d) with no changes in the fraction of NG2 staining in the lesioned area (Fig.4 e-f) and in the percentage 
of NG2+ early progenitors (Fig. 4b). Compared to saline and i-EV injected animals, mice receiving MSC-EVs showed 
enhanced MBP staining (Fig. 4c-d) and decreased NG2 labeling (Fig. 4e-f), consistent with OPC differentiation into 
myelin-sheath forming oligodendrocytes. These results were corroborated by the increase in the density of 
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oligodendrocytes positive for CC1, a myelinating oligodendrocyte marker that stains the cell body [6] (Fig.4g-h), and by 
the decrease in the percentage of NG2+/Sox10+ early progenitors at lesion site (Fig. 4b).  
In young mice, i-EVs also exerted an inhibitory action on OPC maturation, as indicated by decreased MBP staining at the 
lesion site (Fig. 5a-b), while the effect of MSC-EVs was less evident. Compared to i-EVs, MSC-EVs significantly 
increased MBP immunoreactivity (Fig. 5a-b), decreased NG2 staining (Fig. 5c-d) and enhanced the density of CC1+ 
differentiated oligodendrocytes (Fig. 5e-f), but failed to increase remyelination over control levels (Fig. 5a-b and e-f).  
Altogether, these data indicate that, while inflammatory microglia inhibit OPC differentiation and remyelination through 
secretion of i-EVs, MSC-treated microglia release EVs which favor recruitment and transition of NG2 cells into mature 
myelinating oligodendrocytes at the lesion site.  
 
EVs from different sources induce qualitatively and quantitatively different myelin ultrastuctural features  
For a more detailed definition of myelin ultrastructure, we evaluated the remyelination process by EM analysis at 10 dpl 
in the CC of aged lesioned mice that received either i-EVs, or MSC-EVs or saline by a single injection. i-EVs-injected 
mice displayed a higher G ratio (Fig. 4k-m) and thinner myelin (Fig. 4l) compared to saline-injected mice, confirming 
that i-EVs hamper remyelination. By contrast, mice injected with MSC-EVs exhibited a higher percentage of myelinated 
fibers (Fig. 4i-j), lower G ratio (Fig. 4k-m) and higher myelin sheath thickness (Fig. 4l) compared to saline control samples 
and i-EVs-injected mice, consistent with a promoting action of MSC-EVs on myelin repair.   
 
Strong impact of EVs on OPC migration: the role of sphingosine-1-phosphate   
To investigate the molecular mechanisms underlying harmful and protective action of microglia-derived EVs, we set up 
primary OPC cultures, a powerful system with easy access for EVs, which allows to dissect their direct effects. All in 
vitro experiments were performed by exposing OPCs to EVs produced by twice as many microglial cells, in order to keep 
conditions close to physiology. To further explore how the differential activation state of microglia influences EV action, 
NS-EVs were included in the analyses.  
First, we explored whether EVs have the capacity to influence OPC proliferation and/or migration, two mechanisms 
involved in oligodendrocyte recruitment into focal myelin lesion. The impact of EVs on proliferation was assessed by 
exposing cultured OPCs to the different types of EVs for 24h in the presence of the proliferative marker EdU. Quantitative 
analysis of EdU+ OPCs showed that i-EVs reduce OPC proliferation, albeit with no statistical significance, while EVs 
produced by pro-regenerative microglia (either IL4-EVs or MSC-EVs) significantly increased OPC proliferation 
compared to i-EVs-treated, but not to NS-EVs or untreated (control) OPCs (Fig. 6a-b). In agreement with in vivo 
observations, these data show very mild effects of EVs on OPC proliferation. By contrast, the impact of EVs on OPC 
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migration was much stronger. Using a classical transwell-based migration assay, we found that all types of EVs 
significantly enhance the transit of OPCs through the transwell filter, regardless of the activation state of parent microglia 
(Fig. 6c).  
EVs contain components of the sphingolipid pathway, which play a key role in biogenesis and biological action of EVs 
[94]. Among them, sphingosine-1-phosphate (S1P) is a known chemoattractant agent [49], which may be involved in 
OPC migration. To test this hypothesis we pulse-labelled microglia with [3H]sphingosine ([3H]sph) under conditions of 
metabolic equilibrium, and measured the content of [3H]sphingolipids in EVs and parental cells. We found detectable 
levels of [3H]S1P along with more abundant sphingolipids (sphingomyelin, lactosylceramide and 
monosialodihexosylganglioside (GM3) in EVs produced by NS microglia, but S1P was not enriched in EVs compared to 
donor cells (Table III). We next monitored OPC migration in the presence of the pan S1P receptor antagonist S-FTY720-
Vinylphosphonate (100 nM) [92] and found that the drug completely inhibited the capacity of EVs to attract OPCs (Fig. 
6d).  
Collectively these results indicate that microglial EVs promote OPC migration and highlight a role for vesicular S1P as 
attractive guidance cue for OPCs.  
 
Table III: Sphingolipid content in EVs and parental microglia. 
 
Sphingolipid species % in cells % in EVs EVs/cell fold increase 
[3H]Sphingomyelin 27.55 ± 2.4 33.88 ± 3.4 1.2 
[3H]Ceramide 4.04 ± 0.4 4.60 ± 0.4 1.1 
[3H]Glucosylceramide 5.97 ± 0.5 4.41 ± 0.4 0.7 
[3H]Lactosylceramide 19.26 ± 1.8 11.41 ± 1.4 0.6 
[3H]Sphingosine 3.78 ± 0.4 4.31 ± 0.5 1.1 
[3H]GM3 10.4 ± 0.6 8.94 ± 1.0 0.8 
[3H]Sphingosine-1-phosphate 1.17 ± 0.14 0.95 ± 0.15 0.8 
 
 
In vitro, EVs derived from both inflammatory and pro-regenerative microglia promote OPC differentiation 
To define direct effects of EVs on OPC differentiation, cells were incubated with the different types of EVs for 48h, fixed 
and stained for MBP. Unexpectedly, immunofluorescence analysis revealed that i-EVs significantly enhanced the fraction 
of MBP+ oligodendrocytes in a similar way to IL4-EVs and MSC-EVs, whereas NS-EVs did not influence OPC 
maturation (Fig. 6e-f). No significant changes in the fraction of MBP+ cells were observed with half or double 
concentration of IL4-EVs, excluding the possibility that small variations in EV amount could have had a strong impact 
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on OPC maturation (normalized MBP+ OPC fraction: 1.53 + 0.26 standard EV dose; 1.42 + 0.22 half dose; 1.27 + 0.36 
double dose). Western blot analysis confirmed that IL4-EVs enhance the expression of MBP along with other markers of 
mature oligodendrocytes, i.e. 2′,3′-cyclic nucleotide-3′-phosphodiesterase (CNPase) and glutathione S-transferase (GST)-
pi while downregulating GPR17, a marker of immature oligodendrocytes (Fig. 6g).  
Direct action of EVs on myelin deposition was investigated in OPCs co-cultured with DRG neurons, a useful system to 
study myelination [16]. OPCs were exposed to EVs for 11 days (three treatments, every three/four days), fixed and 
immunostained with axon- and myelin-specific markers, i.e. high-molecular-weight neurofilaments (NF) and MBP, 
respectively. Quantitative analysis of the linear MBP+ segments extending along axons showed that both IL-4-EVs and 
MSC-EVs favoured myelin deposition (Fig. 6h-i). However, i-EVs also significantly enhanced myelination, albeit at a 
lower extent compared to pro-regenerative EVs. NS-EVs had no significant effect on myelination (not shown). Of note, 
MSC-EVs displayed higher capacity to promote myelin deposition compared to EVs released by MSCs (Suppl. Fig. 4a, 
Online Resource).  
Globally, these results show that i-EVs exhibit direct pro-differentiating action on cultured OPCs. Thus, the blockade of 
OPC maturation caused by i-EVs in vivo likely involves other brain cells, which may acquire harmful function in response 
to i-EVs. 
 
Astrocytes mediate the harmful effects of i-EVs on OPCs 
Recent evidence indicates that microglia can transform astrocytes into A1 harmful cells, which inhibit OPC 
differentiation [99]. To investigate the possible involvement of astrocytes in the detrimental action of i-EVs, we grew 
OPCs on top of astrocytes and maintained the co-culture in the presence or absence of i-EVs for 48 hrs. 
Immunofluorescence staining for MBP revealed that, in the absence of microglial i-EVs, astrocytes accelerated OPC 
differentiation, as indicated by higher percentages of MBP/Olig-2 double-positive cells in astrocyte-OPC co-cultures 
compared to OPCs cultured alone (Fig.7a-b). However, when exposed to i-EVs, astrocytes caused a strong inhibition of 
OPC maturation (Fig. 7a-b). Consistent with harmful astrocyte transformation, qPCR analysis showed that, in response 
to i-EVs, pure cultured astrocytes upregulated the A1 reactive markers serping-1 and Amigo 2 [55] (Fig. 7c), whilst 
exhibiting  unaltered expression for the A2 markers pentraxin-3 (PTX3), CD14 and Tm4sf1 (Fig. 7d). In contrast, the 
lipid extract of i-EVs potently induced A2 markers (Fig. 7d), and slightly increased serping-1 and Amigo 2 (Fig. 7c), 
suggesting a shift of astrocytes towards beneficial rather than harmful functions. This indicates that other i-EVs 
components (proteins and/or RNAs) are mostly responsible for harmful astrocyte transformation. A1 astrocyte conversion 
likely occurred also in vivo in LPC-treated mice that received i-EVs for 4 days (Fig. 3a). Indeed, GFAP- positive 
astrocytes, present at myelin lesion, showed decreased PTX3 labelling and increased, albeit non significant, 
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immunoreactivity for the A1 marker C3a compared to saline-injected mice (Fig. 7e-f) No major changes in A1 and A2 
markers occurred at protein and mRNA levels in astrocytes exposed to MSC-EVs in vivo and in vitro (Fig. 7c-f).  
Three microglial mediators have been shown to be both necessary and sufficient for A1 astrocyte conversion, i.e. IL-1a, 
C1q and TNFα. Of them, TNFα and IL1-a are mostly released by immune cells in EV-associated form [29] [86], while 
both TNFα and C1q were previously detected in microglia-derived EVs [25] [17] [98]. To assess the involvement of IL-
1a, C1q and TNFα in A1 astrocyte transformation, cytokine profile of i-EVs was assessed with specific ELISA. Detectable 
amounts of IL-1a, C1q and TNFα were found in i-EVs isolated from 15x106 microglial cells (IL1-a ~90 pg; C1q content 
~ 78 pg; TNF-α content ~ 613 pg), supporting their role in harmful astrocyte transformation. Among the three 
inflammatory mediators, only TNF-α was suppressed in parental microglia by MSC conditioning at both protein and 
mRNA levels, as determined by ELISA (Fig. 7g) and qPCR (Fig. 2b). We therefore measured the TNFα content in i-EVs 
and MSC-EVs. i-EVs displayed about 3-fold higher levels of TNF-α compared to MSC-EVs (i-EVs TNF-α content ~ 613 
pg; MSC-EVs TNF-α content ~168 pg), suggesting that the capacity of MSC-EVs to promote myelin repair may occur, 
at least in part, via TNF-α suppression. To assess TNF-α involvement in astrocyte activation, we pre-treated i-EVs with 
Etanercept (ETN, 200 ng/ml), a TNF-α inhibitor, before co-exposing astrocytes to i-EVs and ETN. qPCR analysis showed 
that TNF-α inactivation prevented serping-1 upregulation and induced PTX3 expression in vitro, suggesting a shift of 
cultured astrocytes towards beneficial function (Fig. 7c-d). Immunolabelling for C3 in vivo revealed a significant decrease 
in the density of astrocytes positive for the A1 marker at lesions co-injected with i-EVs and ETN compared to i-EVs 
alone. However, PTX3 staining showed that the inhibitor caused by itself  a decrease in  the density of PTX3 positive 
astrocytes, being not able  to prevent the decrease in PTX3+ astrocytes induced by i-EVs (Fig. 7e-f). Taken together these 
data indicate that TNF-α is essential for to the astrocyte response, despite its inactivation is not sufficient to prevent 
harmful astrocyte transformation in vivo.  
 
EVs binds to the OPC cell surface 
While mechanisms underlying astrocyte reaction to microglial EVs have been previously studied [95] [25], how EVs 
influence OPC activity is completely unknown. We explored whether EVs physically interact with OPCs. We placed 
single EV in contact with cultured OPCs using optical tweezers and monitored EV-OPC dynamics using time lapse 
microscopy (Fig.8a). We observed that about 70% of NS-EVs adhered to the OPC surface (17 out of 24), suggesting that, 
in principle, most EVs could influence OPC function.  
 
The pro-differentiation activity of EVs depends on the lipid components of EVs 
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To investigate whether direct effects of EVs were mediated by factor(s) present at the surface or in the lumen of EVs, IL-
4-EVs or MSC-EVs were busted by hypo-osmotic shock [34] and membrane fragments pelleted to remove soluble 
components were added to cultured OPCs. Broken EVs, depleted of their content, retained the capability to promote OPC 
maturation (Fig. 8d), revealing that surface component(s) of EVs were mainly driving this process. To distinguish between 
protein and lipid component(s), we exposed OPCs to the lipid fraction of IL4-EVs (Fig. 8e) or i-EVs (not shown). EV 
lipids enhanced OPC maturation even more efficiently than intact EVs (Fig. 8e), indicating that the pro-differentiating 
activity of EVs is mostly attributable to their lipid components. Finally, given that previous studies have shown that S1P 
and its analog FTY720-p promote OPC  differentiation and myelin deposition [65] [23], we asked whether vesicular S1P 
may be implicated in the pro-differentiating activity of the EVs. We treated OPCs with the S1P receptor antagonist S-
FTY720-Vinylphosphonate and found no changes in EV-induced OPC differentiation to MBP+ oligodendrocytes (Fig.8f), 
thus ruling out a role of vesicular S1P in OPC maturation. 
 
DISCUSSION 
Our study reveals a previously unrecognized role of EVs produced by microglia in the control of remyelination, the 
spontaneous process by which OPCs differentiate into myelin-forming cells, restore myelin sheaths to protect axons from 
degeneration and allow fast signal transmission [24]. Specifically, we show that exogenous EVs from differentially 
conditioned microglia exert opposite effects on remyelination, with either pro-regenerative or detrimental actions, 
depending on the type of conditioning stimulus. Importantly, our study also unveils an unprecedented role for astrocytes 
in mediating the detrimental effects of EVs from pro-inflammatory microglia. Finally, it gives a first identification of the 
distinct molecular components of EVs involved in astrocyte detrimental transition as well as in promotion of OPC 
migration and/or differentiation, thus unveiling new targets for modulation of myelin repair.  
 
EVs mediate microglial action on oligodendrocytes 
Previous evidence had shown that microglial phenotype strongly influences remyelination [30] [72] and that a 
predominant pro-regenerative response of microglia is required for efficient myelin repair after damage [64]. However, 
the mode(s) of action of microglia in fostering or inhibiting myelin repair was largely unclear. In the present study, by 
utilizing a combined approach (immunohistochemistry and EM), we unequivocally show that EVs released by pro-
regenerative microglia promote OPC recruitment and differentiation at LPC-induced myelin lesions, while i-EVs, derived 
from inflammatory microglia, block remyelination. Our study advances current knowledge by showing that i) dark, 
reactive microglia are recruited at myelin lesion and release EVs, as indicated by EM, and ii) EVs are sufficient to mediate 
either detrimental or beneficial function on myelin forming cells, reflecting the phenotype of donor microglia, upon 
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exogenous administration to the lesion site. EVs remain intact for a short time at the injection site, likely as a consequence 
of lysosomal degradation [15] or cell fusion and cargo dilution [75], but cause a prolong modulation of oligodendrocytes 
surrounding the lesion. This is in line with a recent study showing that microglial EVs engineered to deliver an anti-
inflammatory cytokine IL-4 induce a long lasting immune modulation in the EAE model of multiple sclerosis [15] . 
However, whether EVs with opposite action on OPCs may be generated endogenously by microglia and may be relevant 
for the course of de- and re-myelination in animal models of MS still remains unclear. Selective tools to manipulate 
endogenous EV production are needed to overcome this limitation of our study and to analyze the role of microglial EVs 
in a more physiological setting. 
 
A1 astrocytes mediate detrimental action of i-EVs on OPCs 
The major finding of this paper is the demonstration that astrocytes mediate the detrimental action of inflammatory 
microglia-derived EVs on OPCs. While i-EVs by themselves favor differentiation of OPCs in monoculture, they cause 
a clear block of OPC maturation when OPCs are cocultured with astrocytes, thereby mimicking the inhibitory action of 
i-EVs at myelin lesion in the in vivo LPC-demyelination model. Importantly, inhibition of OPC maturation in the 
OPC/astrocytic co-cultures is likely paralleled by conversion of astrocytes into A1 harmful cells. Indeed, our previous 
work revealed that cultured astrocytes become hypertrophic and upregulate inflammatory markers when exposed to i-
EVs [95]. By analyzing the expression and immunoreactivity of a few specific A1 and A2 markers in this study, we 
suggest that astrocytes acquire a harmful A1 phenotype both in vitro and in the LPC-mouse model of myelin lesion. A1 
astrocytes were recently proven to slow OPC differentiation and to damage differentiated oligodendrocytes [99] [20], 
and have been observed in demyelinating plaques of MS patients [55]. By showing that microglial i-EVs cause A1 
astrocyte transformation, we add an important piece of information towards the understanding of the mechanism 
possibly responsible for remyelination failure in MS. We hypothesize that demyelinating lesions may fail to 
remyelinate because EVs produced by chronically activated microglia block OPC differentiation by inducing harmful 
astrocyte conversion, thus nullifying the direct pro-myelinating action of EVs. In line with our study, previous works 
highlighted the detrimental effect of chronically activated astrocytes on myelin repair, by showing that depletion of 
reactive astrocytes at the chronic phase of EAE improves EAE clinical outcome [62] and that remyelination by 
transplanted OPCs is less extensive in areas of demyelination that contain astrocytes than in astrocyte-free areas [8]. 
A few proteins released by astrocytes, including CXCL10 [67] and endothelin-1 [42], inhibit OPC maturation and may 
be involved in remyelination failure. By contrast, no molecules with the capacity to damage OPCs/oligodendrocytes have 
been identified so far in the secretome of inflammatory microglia, which rather contains protective agents for myelin-
forming cells [63] [24]. 
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EV signals driving astrocytes towards oligotoxic cells 
Although our analysis indicates that EVs carry the glycolipid lactosylceramide (LacCer) and S1P, known inducers of pro-
inflammatory astroglial activation in EAE [62] [19] [81], the lipid extract of i-EVs does not drive harmful transformation 
in cultured astrocytes, implicating the protein and/or RNA cargoes of i-EVs in the acquisition of detrimental astroglial 
function. Previous studies reported that activated microglia release three mediators that are necessary and sufficient for 
astrocyte conversion to harmful cells, i.e. TNF-α, IL-1a and C1q [55]. Here we show that i) i-EVs carry the three inducers 
of A1 astrocytes, ii) TNF-α is decreased in MSC-EVs, which do not cause harmful astrocyte transformation, and iii) TNF-
α inactivation partially inhibits the proinflammatory astrocyte response. Besides identifying TNF-α as a target of MSC 
action in microglia, this evidence implicates vesicular TNF-α in the astrocyte shift towards oligotoxic cells. However, 
other molecules may be sorted in MSC-EVs, such as TGF-β or FGF [2], which may counteract the action of the 
inflammatory cargoes, preventing A1 astrocyte activation. 
Elevated production of TNF-α was previously reported in the serum, cerebrospinal fluid and brain plaques of MS patients 
[59], correlating with disease severity or exacerbation [58] [93]. In addition, it was recently shown that TNF-α is mostly 
produced by microglia and macrophages in acute and progressive EAE, enhancing clinical disability [91]. Whether the 
content of TNF-α is elevated in microglial EVs of MS patients, especially those with progressive MS, is an important 
question for future studies, that may lead to the identification of novel disease biomarkers. In devising possible therapeutic 
strategies to promote myelin repair it should be noted, however, that TNF-α has been attributed both detrimental and 
protective roles in MS. Specifically, the membrane bound form of the cytokine was shown to sustain reparative processes 
via activation of type 2 TNF-α receptor  (TNFR2) in oligodendrocytes [13], preventing the clinical use of  TNF-α blockers 
in MS [47]. 
 
Key role of lipids in the pro-myelinating action of EVs  
Another key observation of our study is that the lipid content of all types of microglial EVs has a direct impact on OPCs, 
directing both their recruitment and differentiation.  
Through measurement of sphingolipid content and the use of a potent S1P receptor antagonist S-ene-FTY720 
Vinylphosphonate, we show that S1P is secreted by microglia in association with EVs and acts as an attractive guidance 
cue for OPCs. Although the recent use of the S1P analog fingolimod/FTY720, which activates S1P receptors, to treat MS 
has fueled research on the direct effects of S1P on oligodendrocytes [38], to our knowledge, our data provide the first 
demonstration of a central role for EVs-associated S1P in OPC migration, the first key step in myelin repair. Other 
chemotactic molecules, such as Wnt3a [45] and the endocannabinoid anandamide [34] are packaged in microglial EVs, 
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revealing the important role of EVs as vehicles of chemotactic signals [52]. Through EV fractionation, we also show that 
lipids of all EV types drive OPC maturation, making lipid research a hotspot in the field of myelin repair. We rule out the 
involvement of S1P in the pro-differentiating action of EVs, since the capacity of EVs to accelerate OPC maturation was 
unchanged under pharmacological blockade of S1P receptors. We anticipate that identification of lipids responsible for 
the pro-differentiating action of microglial EVs may help to design new therapeutics to foster myelin repair.  
Previous studies implicated the miRNA cargo of EVs in myelin repair, rather than the lipid content. Pro-myelinating 
exosomes derived by peripheral immune cells were previously identified in rat serum [76] [77]. Their pro-differentiating 
activity was partially ascribed to the delivery of miR-219 to OPCs, a microRNA that regulates multiple genes in the 
differentiation pathway [76] . Although miR-219 is present in EVs derived from microglia and is upregulated in i-EVs 
[75], our biochemical experiments indicate that the lipid fraction of EVs, which is free of nucleic acids, retains the ability 
to drive OPC maturation, arguing against a major involvement of miRNAs in the direct pro-differentiating action of 
microglial EVs. Nevertheless, the RNA and/or protein cargoes of EVs may indirectly regulate OPC maturation by 
influencing the microenvironment around the lesion. 
 
The unique pro-myelinating activity of EVs derived from microglia co-cultured with MSC  
We show that MSC-EVs have a unique capacity to stimulate the endogenous reparative response of OPCs at myelin 
lesion. The pro-myelinating action of MSC-EVs exceeds that of IL4-EVs both in vitro and in vivo. This suggests that well 
known effects of MSCs in EAE rely, at least in part, on the paracrine effect of MSCs on microglia phenotype and microglia 
communication with OPCs and astrocytes during remyelination. Further work remains to be done to define the minimal 
components of MSC-EVs required to drive efficient remyelination. Selected luminal components of MSC-EVs (proteins 
and/or RNAs) in combination with pro-differentiating lipid(s) may be assembled in EV mimetics of low complexity and 
with low chance of off-target effects, which may be ideal tools to develop novel therapeutic approaches in chronic MS. 
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FIGURE LEGENDS 
Figure 1. Microglia infiltrating the myelin lesion release EVs. a-c EM images of the CC showing dark cells resembling 
microglia (a), oligodendrocytes (b) and astrocytes (b) infiltrating demyelinated lesion at 10dpl. High magnification inserts 
in c show examples of EVs budding from the surface of dark microglia (Scale bars, 2 μm). 
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Figure 2. Production and characterization of EVs released by microglia with different activation states.  a Scheme 
of microglia polarization in vitro. b Gene expression of inflammatory markers (IL-1a, C1q, TNF-α, IL-1β and iNOS), 
pro-regenerative markers (Arg1 and Socs-3) and the metabolic gene Chpt1 in unstimulated microglia (NS-MG), IL-4-
treated microglia (IL-4-MG) or microglia stimulated with inflammatory cytokines in the absence (i-MG) or in the 
presence of MSCs (MSC-MG) (number of independent experiments (n) =7-11/group; Kruskal-Wallis test with Dunn’s 
multiple comparison *p<0.05, **p<0.01, ***p< 0,001. c Representative cryo-EM images of the heterogeneous  
population of microglial EVs in the 100k g pellet. d Size profile of EVs pelleted from 1X106 microglia, re-suspended in 
100 μl of 0.1 µm-filtered PBS and analysed using NTA (top). Histograms show production of EVs from NS or polarized 
microglia during 30 min stimulation with 1mM ATP (bottom) (n=4; One Way ANOVA p=0,2898 with Tukey's multiple 
comparisons test). e Mean Raman spectra obtained using 532 nm laser line from EVs of NS or polarized microglia. All 
spectra were baseline corrected, aligned and normalised before averaging. f Multivariate statistical analysis performed on 
the Raman spectra (n ≥ 30 per sample). The scatter plot represents the values obtained for the Canonical Variable 1 and 
Canonical Variable 2 after LDA. In the classification model, spectra from EVs were grouped based on the cell of origin 
to test RS ability to discriminate the molecular composition of EVs from different microglial phenotypes. The first 10 PC 
scores calculated by means of PCA were used for the LDA. Each dot represents a single spectrum.  
 
Figure 3. Action of EVs on early response to EVs. A Experimental design of EV delivery to LPC-treated mice during 
the phase of OPC recruitment. b-c Histograms show the density of total proliferating cells (b) (Number of animals (N)= 
3-5/group; One Way ANOVA main effect of treatment p=0,0021 with Holm-Sidak's multiple comparisons test vs Saline) 
and the percentage of BrdU+ proliferating OPCs (c) (N=3-5/group; One Way ANOVA p=0,0165 with Holm-Sidak's 
multiple comparisons test vs Saline) in saline, i-EVs- IL4-EVs- or MSC-EVs-injected lesions. d Representative images 
of Saline, i-EVs, IL4-EVs or MSC-EVs-injected lesions (area delimited by dotted line) immunostained against Sox10 
(red) (Scale bars of images and insets, 50 μm). Low magnification inserts show Sox10/DAPI double staining to visualize 
nuclei. e Corresponding density of Sox10+ cells (histograms) (N=3-5/group; One Way ANOVA p=0,0013 with Holm-
Sidak's multiple comparisons test vs Saline) and percentage of immature (NG2+ Sox10+) oligodendrocytes (red line) 
(N=3-5/group; One Way ANOVA p=0,0074 with Holm-Sidak's multiple comparisons test vs Saline).  f-h Representative 
images of saline, i-EVs, IL4-EVs or MSC-EVs-injected lesions (area delimited by dotted line) immunostained against 
MBP (green) and DAPI (blue) (f) or against NG2 (green), Sox10 (red) and DAPI (blue) (h) (Scale bars, 50 μm). g, i 
Histograms show the percentage of the lesioned area immunoreactive for MBP (g) (N=3-7/group; One Way ANOVA 
p=0,0001 with Holm-Sidak's multiple comparisons test vs Saline) or  NG2 (i) (N=3-4/group; One Way ANOVA p=0,0173  
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with Holm-Sidak's multiple comparisons test vs Saline) in saline-injected mice and mice that received different types of 
EVs. 
 
Figure 4. Action of EVs on myelin deposition in acute LPC-mediated focal demyelination. a Experimental protocol 
of EV delivery to LPC-treated mice during the phase of OPC differentiation. b Histograms show percentage of immature 
(Sox10+NG2+) and differentiated cells (Sox10+NG2-) oligodendrocytes in saline-injected mice and mice that received i-
EVs or MSC-EVs (N=3-4/group; Kruskal-Wallis test p=0,0129 with Dunn's multiple comparisons test vs Saline). c, e, g 
Representative images of saline, i-EVs or MSC-EVs-injected lesions (area delimited by dotted line), immunostained 
against MBP (green, c), NG2 (green, e), or CC1 (yellow, g) (Scale bars, 50 μm). d, f, h Histograms show the percentage 
of the lesioned area immunoreactive for MBP (d) (N=3-4/group; One Way ANOVA p<0,0001 with Holm-Sidak's 
multiple comparisons test), NG2 (f) (N=4/group; One Way ANOVA p<0,0001 with Holm-Sidak's multiple comparisons 
test) or the density of mature oligodendrocytes (CC1) (h) (N=3/group; One Way ANOVA p<0,0001 with Holm-Sidak's 
multiple comparisons test. i Representative electron micrographs of CC in saline-injected mice and mice that received i-
EVs or MSC-EVs (Scale bars of images, 1 μm; original magnification 25000). J Histograms show the percentage of 
unmyelinated/myelinated fibers (N=3/group; One Way ANOVA p=0.039 with Dunn's multiple comparison test). k 
Myelin thickness can be quantified by the G-ratio, defined as the ratio between the the inner (axonal, d, white) and outer 
(overlying myelin, D, yellow) diameters of myelinated axons. Scale bar of image, 1.5 μm. l Histograms show 
quantifications of the G-ratio (N=3/group; Kruskal-Wallis test p< 0,0001 with Dunn's multiple comparisons test). m 
Histograms show myelin sheath thickness (N=3/group; Kruskal-Wallis test p< 0,0001 with Dunn's multiple comparisons 
test). Each dot represents an individual value. n Scatter plots of G-ratio against axon diameter. The G-ratio of each 
measured myelinated fiber is indicated by a single circle (n=160 saline, n=167 MSC-EVs, n=169 i-EVs). Correlation 
between axon diameter (x1) and g-ratio (y1) is expressed by the correlation coefficient (r) of the linear regression curve 
(saline: r=0.503, i-EVs: r=0.518; MSC-EVs: r=0.448). 
 
Figure 5.  Action of microglia-derived EVs on OPC differentiation at myelin lesion in young mice. a, c, e 
Representative images of saline, i-EVs and MSC-EVs-injected lesions (area delimited by dotted line), immunostained 
against MBP (green, a), NG2 (green, c), or CC1 (yellow, e) (Scale bars, 50 μm). Low magnification inserts show double 
labeling for DAPI. b, d, f Histograms show the percentage of the lesioned area immunoreactive for MBP (b),  NG2 (d) 
or CC1 (f) at 7dpl in saline-injected mice and mice injected with i-EVs or MSC-EVs. (Number of animals (N) = 3-
5/group, One way ANOVA with Holm-Sidak’s multiple comparison: MBP, p=0,0012; NG2, p< 0,0001; CC1, p=0,0090). 
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Figure 6. EV impact on OPC migration, differentiation and myelination. a-b Fluorescence images of cultured OPCs 
incubated with EdU (red), fixed and stained for NG2 (green) and DAPI (Blue) after 24h exposure to i-EVs or MSC-EVs 
(Scale bars, 50 µm). The histograms in b show the percentage of EdU+ OPCs in cultures exposed or not to different EV 
types. Data have been normalized to control (number of experiments (n) =5-8 /group; Kruskal-Wallis test p< 0,0001 with 
Dunn's multiple comparisons test). c Histograms show the percentage of OPCs migrated through the filter of the Boyden 
chamber in control conditions and following addition of different types of EVs. Data have been normalized to control 
(n=3; One Way ANOVA p=0,0054 with Holm-Sidak's multiple comparisons test vs control). d Percentage of migrated 
OPCs in response to S1P or IL-4-EVs in the presence or in the absence of the S1P receptor antagonist S-FTY720-
Vinylphosphonate (n=3; Kruskal-Wallis test p< 0,0001 with Dunn's multiple comparisons test). e Representative images 
of OPCs maintained in control conditions or exposed to different types of EVs for 2 days, fixed and stained for MBP 
(red), GPR17 (green) and DAPI (blue) (Scale bars, 50 µm). f. Corresponding quantification of MBP+ OPCs. Data have 
been normalized to control (n=5-8/group, Kruskal-Wallis test p< 0,0001 with Dunn's multiple comparisons test vs 
control). g Western blot of control OPCs and IL4-EVs-treated OPCs for the indicated markers of OPC differentiation. 
Tubulin has been used as loading control. Relative quantification of the band density is shown on the right (n=3; CNPase: 
Unpaired t test p=0,0033; MBP: Unpaired t test p=0,0018; GST-pi: Unpaired t test p< 0,0001; GPR17: Unpaired t test 
p=0,0224). h Representative images of OPC-DRG co-cultures maintained in control conditions or exposed to i-EVs, IL4-
EVs or MSC-EVs for 11 days, fixed and stained for MBP (red) and neurofilament (NF, green) (Scale bars, 20 µm). e 
Myelination index (MBP staining/NF staining) under different experimental conditions (n=3; Kruskal-Wallis test p< 
0,0001 with Dunn's multiple comparisons test vs control). 
 
Figure 7. Astrocytes transform the pro-differentiating action of i-EVs to inhibitory activity. a Representative images 
of OPCs cultured alone or with astrocytes in the presence or in the absence of i-EVs immunostained for MBP (red), Olig2 
(green) and GFAP (cyan) (Scale bars, 20 μm). b Corresponding quantifications of MBP+ OPCs (n=2; One way ANOVA 
p< 0,0001 with Tukey's multiple comparisons test). c-d Representative qPCR analysis of A1 (c) and A2 (d) marker 
expression in unstimulated astrocytes (control), astrocytes exposed to i-EVs, the lipid fraction of i-EVs (lipids), MSC-
EVs (left panels). Right panels show A1 and A2  marker expression in astrocytes exposed to i-EVs in the presence/absence 
of the TNF-a inhibitor etanercept (ETN).Three replicates/condition have been normalized to control (One way ANOVA 
p<0,0001 with Holm-Sidak's multiple comparisons test).  e Representative images of saline, i-EVs, or MSC-EVs-injected 
lesions, immunostained against C3 or PTX3 (red) and Hoechst (blue) (Scale bars, 50 μm). High magnification inserts 
show astrocytes double stained for GFAP (green) and C3 or PTX3 (red). f  Density of C3- and PTX3-positive astrocytes 
at saline, i-EVs-, i-EVs+ETN,or MSC-EVs-injected lesions (C3, number of sections=5-10/group; Kruskal-Wallis test p= 
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0,0298 with Dunn's multiple comparisons test among Saline, i-EVs and i-EVs+ETN); (PTX3, number of sections=5-
10/group; Kruskal-Wallis test p< 0,0001 with Dunn's multiple comparisons test).  g ELISA quantification of IL-1a, C1q, 
and TNF-α in 1X106 inflammatory microglia (i-MG) and in MSC-treated microglia (MSC-MG) (n=3; IL-1a, Mann 
Whitney t-test p=0,9000; C1q, unpaired t test p=0,5619; TNF-α, Mann Whitney t-test p=0,0286). 
 
Figure 8. EVs efficiently interact with OPCs. a Schematic representation of EV delivery to OPCs by optical tweezers. 
EVs are first trapped above the OPCs by the IR laser tweezers (left), then the stage is moved in plane (XY) and the 
objective/trap is moved axially (Z) to set the EVs in contact with the OPCs (middle). The trapping laser is switched off 
to check whether EV adheres to the neuron membrane (right). a’ Sequence of phase-contrast images showing one example 
of EV driven to an OPC following the procedure described in a (Scale bar, 10 μm). b-c OPCs were maintained in control 
condition or exposed to intact EVs, broken EVs or the lipid extract of EVs for 2 days, fixed and stained for MBP. 
Histograms show the percentage of mature MBP+ oligodendrocytes in cultures exposed to broken EVs derived from IL-
4 microglia (Brk IL4-EVs) or MSC-treated cells (Brk MSC-EVs) (b; n=3; Kruskal-Wallis test p=0,0049 with Dunn's 
multiple comparisons test versus control), intact EVs or native lipids (lipids) extracted from IL4-EVs (c; One Way 
ANOVA p=0,0001 with Holm-Sidak's multiple comparisons test). Data have been normalized to control. d Percentage of 
differentiated MBP+ oligodendrocytes in cultures exposed for 2 days to i-EVs alone or in combination with S-FTY720-
Vinylphosphonate, FTY720-Vinylphosphonate alone or S1P. Data have been normalized to control (n=3; Kruskal-Wallis 
test p=0,0009 with Dunn's multiple comparisons test versus control). 
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Dear Editor, 
We are hereby submitting the revised version of our manuscript “Detrimental and protective action of 
microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure. We have 
found the reviewers’ comments very constructive, and have thoroughly revised the manuscript according to 
their suggestions. 
In this context, we have performed new experiments to explore the fate of microglial EVs at myelin lesion 
and show that EVs have a short half-life, being no longer visible in proximity or away from the lesion one 
hour after injection. In addition, we now identify TNF-a as one of the actual mediators of i-EVs underlying 
astrocyte pro-inflammatory activation. These new data have been included as Supplementary Figure 3 and 
Figure 7 c-d in the revised manuscript. 
 We thank the reviewers for their suggestions which we feel have greatly improved our manuscript and we 
hope the reviewers will deem our changes as reflecting their requirements for publication in Acta 
Neuropathologica. 
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